WO2002026971A1 - Nouveau polypeptide, facteur de transcription humain lcr-f112.1, et polynucleotide codant ce polypeptide - Google Patents

Nouveau polypeptide, facteur de transcription humain lcr-f112.1, et polynucleotide codant ce polypeptide Download PDF

Info

Publication number
WO2002026971A1
WO2002026971A1 PCT/CN2001/001094 CN0101094W WO0226971A1 WO 2002026971 A1 WO2002026971 A1 WO 2002026971A1 CN 0101094 W CN0101094 W CN 0101094W WO 0226971 A1 WO0226971 A1 WO 0226971A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
polynucleotide
transcription factor
human transcription
factor lcr
Prior art date
Application number
PCT/CN2001/001094
Other languages
English (en)
French (fr)
Inventor
Yumin Mao
Yi Xie
Original Assignee
Shanghai Biowindow Gene Development Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Biowindow Gene Development Inc. filed Critical Shanghai Biowindow Gene Development Inc.
Priority to AU2002210328A priority Critical patent/AU2002210328A1/en
Publication of WO2002026971A1 publication Critical patent/WO2002026971A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention belongs to the field of biotechnology. Specifically, the present invention describes a novel polypeptide ⁇ ⁇ transcription factor LCR-F112. 1, and a polynucleotide sequence encoding the polypeptide. The invention also relates to a preparation method and application of the polynucleotide and polypeptide.
  • Hemoglobin is the main component of red blood cells in spinal animals, and it is responsible for transporting oxygen and carbon dioxide in the body.
  • Each hemoglobin molecule consists of two identical four subunits and four heme, and hemoglobin without heme becomes globin.
  • the genes of all globin subunits have very similar structures.
  • the composition of subunits of hemoglobin varies at different stages of individual development. Transcription and expression of globin subunits in vivo are regulated by related transcription factors. Transcription factor LCR regulates the transcription and expression of globin ⁇ , ⁇ and P subunits in the body. It has two important activities in the body. First, it binds to the chromosome containing the globin P subunit gene.
  • the transcription factor LCR-F1 plays an extremely important role in the process of globin formation in the body.
  • the mutation or abnormal expression of this protein will cause abnormal formation of relevant hemoglobin in the body, and then affect the occurrence of various related metabolic pathways. It is usually closely related to the occurrence of various respiratory metabolic disorders and related material metabolic disorders in the body. It can also be used for the diagnosis and treatment of various related diseases mentioned above.
  • the human transcription factor LCR-F112. 1 protein plays an important role in regulating important functions of the body such as cell division and embryonic development, and it is believed that a large number of proteins are involved in these regulatory processes, so the identification of more participation has been required in the field These processes are the human transcription factor LCR-F112. 1 protein, and in particular the amino acid sequence of this protein is identified.
  • the isolation of the new human transcription factor LCR-F112. 1 protein encoding gene also provides a basis for research to determine the role of this protein in health and disease states. This protein may form the basis for the development of diagnostic and / or therapeutic drugs for diseases, so it is important to isolate its coding DNA.
  • An object of the present invention is to provide an isolated novel polypeptide-human transcription factor LCR-F112. 1 and fragments, analogs and derivatives thereof.
  • Another object of the invention is to provide a polynucleotide encoding the polypeptide.
  • Another object of the present invention is to provide a recombinant vector containing a polynucleotide encoding the human transcription factor LCR-F112.1.
  • Another object of the present invention is to provide a genetically engineered host cell containing a polynucleotide encoding the human transcription factor LCR-F112.1.
  • Another object of the present invention is to provide a method for producing the human transcription factor LCR-F112.1.
  • Another object of the present invention is to provide an antibody against the polypeptide of the present invention, the human transcription factor LCR-F112.1.
  • Another object of the present invention is to provide mimic compounds, antagonists, agonists, and inhibitors against the polypeptide of the present invention, a human transcription factor LCR-F112.1.
  • Another object of the present invention is to provide a method for diagnosing and treating diseases associated with abnormality of human transcription factor LCR-F112.1. Summary of invention
  • the present invention relates to an isolated polypeptide, which is of human origin and comprises: a polypeptide having the amino acid sequence of SEQ ID No. 2, or a conservative variant, biologically active fragment or derivative thereof.
  • the The polypeptide is a polypeptide having the amino acid sequence of SEQ ID NO: 2.
  • the invention also relates to an isolated polynucleotide comprising a nucleotide sequence or a variant thereof selected from the group consisting of:
  • sequence of the polynucleotide is one selected from the group consisting of: (a) a sequence having positions 968-1300 in SEQ ID NO: 1; and (b) having a sequence of 1-1474 in SEQ ID NO: 1 Sequence of bits.
  • the present invention further relates to a vector, particularly an expression vector, containing the polynucleotide of the present invention; a host cell genetically engineered with the vector, including a transformed, transduced or transfected host cell; Host cell and method of preparing the polypeptide of the present invention by recovering the expression product.
  • the invention also relates to an antibody capable of specifically binding to a polypeptide of the invention.
  • the invention also relates to a method for screening compounds that mimic, activate, antagonize or inhibit the activity of the human transcription factor LCR-F112. 1 protein, which comprises utilizing the polypeptide of the invention.
  • the invention also relates to compounds obtained by this method.
  • the present invention also relates to a method for in vitro detection of a disease or susceptibility to disease associated with abnormal expression of the human transcription factor LCR-F112. 1 protein, comprising detecting mutations in the polypeptide or a sequence encoding a polynucleotide thereof in a biological sample, or Detection of the amount or biological activity of a polypeptide of the invention in a biological sample.
  • the invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a polypeptide of the invention or a mimetic thereof, an activator, an antagonist or an inhibitor, and a pharmaceutically acceptable carrier.
  • the present invention also relates to the use of the polypeptide and / or polynucleotide of the present invention in the preparation of a medicament for treating cancer, developmental disease or immune disease or other diseases caused by abnormal expression of human transcription factor LCR-F112.1.
  • Figure 1 is a transcription factor of the present invention, LCR-F11 2. 1 and human transcriptional gene microarray expression LCR- F1 comparison of FIG factor.
  • the upper graph is a graph of the expression profile of the human transcription factor LCR-FlU. L, and the lower graph is the graph of the expression profile of the human transcription factor LCR-F1.
  • Figure 2 shows the polyacrylamide gel electrophoresis (SDS-PAGE) of the isolated human transcription factor LCR-F112.1. 12kDa is the molecular weight of the protein. The arrow indicates the isolated protein band.
  • Nucleic acid sequence refers to oligonucleotides, nucleotides or polynucleotides and fragments or parts thereof, and may also refer to the genome or synthetic DM or RNA, they can be single-stranded or double-stranded, representing the sense or antisense strand.
  • amino acid sequence refers to an oligopeptide, peptide, polypeptide or protein sequence and fragments or portions thereof.
  • amino acid sequence in the present invention relates to the amino acid sequence of a naturally occurring protein molecule, such "polypeptide” or “protein” does not mean to limit the amino acid sequence to a complete natural amino acid related to the protein molecule .
  • a protein or polynucleotide “variant” refers to an amino acid sequence having one or more amino acids or nucleotide changes or a polynucleotide sequence encoding it. The changes may include deletions, insertions or substitutions of amino acids or nucleotides in the amino acid sequence or the nucleotide sequence. Variants can have "conservative" changes in which the substituted amino acid has a structural or chemical property similar to the original amino acid, such as the replacement of isoleucine with leucine. Variants can also have non-conservative changes, such as replacing glycine with tryptophan.
  • “Deletion” refers to the deletion of one or more amino acids or nucleotides in an amino acid sequence or nucleotide sequence.
  • “Insertion” or “addition” means that a change in the amino acid sequence or nucleotide sequence results in an increase in one or more amino acids or nucleotides compared to a molecule that exists in nature. "Replacement” refers to the replacement of one or more amino acids or nucleotides by different amino acids' or nucleotides.
  • Bioactivity refers to a protein that has the structure, regulation, or biochemical function of a natural molecule.
  • immunologically active refers to the ability of natural, recombinant or synthetic proteins and fragments thereof to induce a specific immune response and to bind specific antibodies in a suitable animal or cell.
  • An "agonist” refers to a molecule that, when combined with the human transcription factor LCR-F112. 1, can cause the protein to change, thereby regulating the activity of the protein.
  • An agonist may include a protein, a nucleic acid, a carbohydrate, or any other molecule that can bind the human transcription factor LCR-F112.1.
  • Antagonist refers to a compound that binds to the human transcription factor LCR-F112. Molecules that block or regulate the biological or immunological activity of human transcription factor LCR-F112. 1. Antagonists and inhibitors can include proteins, nucleic acids, carbohydrates, or any other molecule that can bind the human transcription factor LCR-F112. 1.
  • Regular refers to a change in the function of human transcription factor LCR-F112. 1, including an increase or decrease in protein activity, a change in binding characteristics, and any other biological property, function, or immunity of human transcription factor LCR-F112.1 Change of nature.
  • substantially pure means substantially free of other proteins, lipids, sugars or other substances with which it is naturally associated.
  • Those skilled in the art can purify the human transcription factor LCR-F112.1 using standard protein purification techniques.
  • the substantially pure human transcription factor LCR-F112. 1 produces a single main band on a non-reducing polyacrylamide gel.
  • the purity of the human transcription factor LCR-F112. 1 polypeptide can be analyzed by amino acid sequence.
  • Complementary refers to the natural binding of polynucleotides by base-pairing under conditions of acceptable salt concentration and temperature.
  • sequence C-T-G-A
  • complementary sequence G-A-C-T.
  • the complementarity between two single-stranded molecules may be partial or complete.
  • the degree of complementarity between nucleic acid strands has a significant effect on the efficiency and strength of hybridization between nucleic acid strands.
  • “Homology” refers to the degree of complementarity and can be partially homologous or completely homologous.
  • Partial homology refers to a partially complementary sequence that at least partially inhibits hybridization of a fully complementary sequence to a target nucleic acid. This inhibition of hybridization can be detected by performing hybridization (Southern imprinting or Nor thern blotting, etc.) under conditions of reduced stringency.
  • Substantially homologous sequences or hybridization probes can compete and inhibit the binding of fully homologous sequences to the target sequence under conditions of reduced stringency. This does not mean that the conditions of reduced stringency allow non-specific binding, because the conditions of reduced stringency require that the two sequences bind to each other as a specific or selective interaction.
  • Percent identity refers to the percentage of sequences that are the same or similar in a comparison of two or more amino acid or nucleic acid sequences. Percent identity can be determined electronically, such as through the MEGALIGN program
  • the MEGA GN program can compare two or more sequences (Higg ins, D. G. and
  • the percent identity between nucleic acid sequences can also be determined by the Clus ter method or by methods known in the art such as: Totun Hein (Hein L, (1990) Methods in enzyraology 183: 625-645). 0 "Similarity” refers to the degree of identical or conservative substitutions of amino acid residues at corresponding positions in the alignment of amino acid sequences.
  • negatively charged amino acids may include aspartic acid and glutamic acid; positively charged amino acids may include lysine and arginine; Similar hydrophilic amino acids may include leucine, isoleucine and valine; glycine and alanine; asparagine and glutamine; serine and threonine; phenylalanine and tyrosine.
  • Antisense refers to a nucleotide sequence that is complementary to a particular DNA or RM sequence.
  • Antisense strand refers to a nucleic acid strand that is complementary to a “sense strand.”
  • Derivative refers to HFP or a chemical modification of its nucleic acid. This chemical modification may be the replacement of a hydrogen atom with an alkyl, acyl or amino group. Nucleic acid derivatives can encode polypeptides that retain the main biological properties of natural molecules.
  • Antibody refers to a complete antibody molecule and its fragments, such as Fa,? ( ⁇ ,) 2 and?, Which specifically bind to the epitope of the human transcription factor LCR-F1121.1.
  • a “humanized antibody” refers to an antibody in which the amino acid sequence of a non-antigen binding region is replaced to become more similar to a human antibody, but still retains the original binding activity.
  • isolated refers to the removal of a substance from its original environment (for example, its natural environment if it is naturally occurring).
  • a naturally-occurring polynucleotide or polypeptide is not isolated when it is present in a living thing, but the same polynucleotide or polypeptide is separated from some or all of the substances that coexist with it in the natural system.
  • Such a polynucleotide may be part of a certain vector, or such a polynucleotide or polypeptide may be part of a certain composition. Since the carrier or composition is not part of its natural environment, they are still isolated.
  • isolated refers to the separation of a substance from its original environment (if it is a natural substance, the original environment is the natural environment).
  • polynucleotides and polypeptides in a natural state in a living cell are not isolated and purified, but the same polynucleotides or polypeptides are separated and purified if they are separated from other substances in the natural state .
  • isolated human transcription factor LCR-F112. 1 means human transcription factor LCR-F112. 1 is substantially free of other proteins, lipids, carbohydrates, or other substances with which it is naturally associated. Those skilled in the art can purify the human transcription factor LCR-F112.1 using standard protein purification techniques. Substantially pure polypeptides produce a single main band on a non-reducing polyacrylamide gel '. The purity of human transcription factor LCR-F112. 1 polypeptide can be analyzed by amino acid sequence.
  • the present invention provides a new polypeptide ⁇ ⁇ transcription factor LCR-F112. 1, which is basically composed of the amino acid sequence shown in SEQ ID NO: 2.
  • the polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide, or a synthetic polypeptide, and preferably a recombinant polypeptide.
  • the polypeptide of the present invention may be a naturally purified product or a chemically synthesized product Or from recombinant cells using prokaryotic or eukaryotic hosts (eg, bacteria, yeast, higher plants, insects, and mammalian cells). Depending on the host used in the recombinant production protocol, the polypeptide of the invention may be glycosylated, or it may be non-glycosylated. Polypeptides of the invention may also include or exclude starting methionine residues.
  • the invention also includes fragments, derivatives and analogs of the human transcription factor LCR-F112.1.
  • fragment refers to a polypeptide that substantially maintains the same biological function or activity of the human transcription factor LCR-F112.1 of the present invention.
  • a fragment, derivative or analog of the polypeptide of the present invention may be: (I) a kind in which one or more amino acid residues are substituted with conservative or non-conservative amino acid residues (preferably conservative amino acid residues), and the substitution
  • the amino acid may or may not be encoded by a genetic codon; or ( ⁇ ) a type in which a group on one or more amino acid residues is replaced by another group to include a substituent; or ( ⁇ ⁇ )
  • Such a polypeptide sequence in which the mature polypeptide is fused with another compound such as a compound that prolongs the half-life of the polypeptide, such as polyethylene glycol
  • a polypeptide sequence in which an additional amino acid sequence is fused into the mature polypeptide (Such as the leader or secretory sequence or the sequence used to purify the polypeptide or protease sequence).
  • such fragments, derivatives and analogs are considered to be within the knowledge of those skilled in the art.
  • the present invention provides an isolated nucleic acid (polynucleotide), which basically consists of a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2.
  • the polynucleotide sequence of the present invention includes the nucleotide sequence of SEQ ID NO: 1.
  • the polynucleotide of the present invention is found from a CDM library of human fetal brain tissue. It contains a full-length polynucleotide sequence of 1474 bases, and its open reading frame 968-1300 encodes 110 amino acids.
  • the polynucleotide of the present invention may be in the form of DM or RNA.
  • DM forms include cDM, genomic DM, or synthetic DNA.
  • DNA can be single-stranded or double-stranded.
  • DNA can be coding or non-coding.
  • the coding region sequence encoding a mature polypeptide may be the same as the coding region sequence shown in SEQ ID NO: 1 or a degenerate variant.
  • a "degenerate variant" refers to a nucleic acid sequence encoding a protein or polypeptide having SEQ ID NO: 2 but different from the coding region sequence shown in SEQ ID NO: 1 in the present invention.
  • the polynucleotide encoding the mature polypeptide of SEQ ID NO: 2 includes: only the coding sequence of the mature polypeptide; the coding sequence of the mature polypeptide and various additional coding sequences; the coding sequence of the mature polypeptide (and optional additional coding sequences); Coding sequence.
  • polynucleotide encoding a polypeptide means including a polynucleotide encoding the polypeptide and including additional Coding and / or non-coding polynucleotides.
  • the invention also relates to variants of the polynucleotides described above, which encode polypeptides or fragments, analogs and derivatives of polypeptides having the same amino acid sequence as the invention.
  • Variants of this polynucleotide can be naturally occurring allelic variants or non-naturally occurring variants. These nucleotide variants include substitution variants, deletion variants, and insertion variants.
  • an allelic variant is an alternative form of a polynucleotide that may be a substitution, deletion, or insertion of one or more nucleotides, but does not substantially change the function of the polypeptide it encodes .
  • the present invention also relates to a polynucleotide that hybridizes to the sequence described above (there is at least 50% between the two sequences, preferably 70% identity).
  • the present invention particularly relates to polynucleotides that can hybridize to the polynucleotides of the present invention under stringent conditions.
  • “strict conditions” means: (1) hybridization and elution at lower ionic strength and higher temperature, such as 0.2xSSC, 0.1 »/» SDS, 6 (TC; or ( 2) Add a denaturant during hybridization, such as 50% (v / v) formamide, 0.1% calf serum / 0.1% Ficol l, 42 ° C, etc .; or (3) only between the two sequences
  • the hybridization occurs only when the identity between them is at least 95%, and more preferably 97%.
  • the polypeptide encoded by the hybridizable polynucleotide has the same biological function as the mature polypeptide shown in SEQ ID NO: 2 and Active.
  • nucleic acid fragments that hybridize to the sequences described above.
  • a "nucleic acid fragment” contains at least 10 nucleotides in length, preferably at least 20-30 nucleotides, more preferably at least 50-60 nucleotides, and most preferably at least 100 nuclei. Glycylic acid or more. Nucleic acid fragments can also be used in nucleic acid amplification techniques (such as PCR) to identify and / or isolate polynucleotides encoding the human transcription factor LCR-F112.1.
  • polypeptides and polynucleotides in the present invention are preferably provided in an isolated form and are more preferably purified to homogeneity.
  • the specific polynucleotide sequence encoding the human transcription factor LCR-F112. 1 of the present invention can be obtained by various methods.
  • polynucleotides are isolated using hybridization techniques well known in the art. These techniques include, but are not limited to: 1) hybridization of probes to genomic or cDNA libraries to detect homologous polynucleotide sequences, and 2) antibody screening of expression libraries to detect cloned polynucleosides with common structural characteristics Acid fragments.
  • the DNA fragment sequence of the present invention can also be obtained by the following methods: 1) isolating the double-stranded DM sequence from the genomic DNA; 2) chemically synthesizing the DM sequence to obtain the double-stranded DM of the polypeptide.
  • genomic DNA isolation is the least commonly used. Direct chemical synthesis of DNA sequences is often the method of choice. The more commonly used method is the isolation of cDNA sequences.
  • the standard method for isolating the cDNA of interest is to isolate mRNA from donor cells that overexpress the gene and perform reverse transcription to form a plasmid or phage CDM library.
  • the construction of cDNA libraries is also a common method (Sambrook, et al., Molecular Cloning, A Laboratory Manua 1, Cold Spring Harbor Laboratory. New York, 1989).
  • Commercially available cDNA libraries are also available, such as different cDNA libraries from Clontech. When polymerase reaction technology is used in combination, even very small expression products can be cloned.
  • the genes of the present invention can be selected from these cDNA libraries by conventional methods. These methods include (but are not limited to): (l) DM-DNA or DNA-RNA hybridization; (2) the presence or absence of a marker gene function; (3) determining the level of the transcript of the human transcription factor LCR-F112. 1; (4) Detecting the protein product of gene expression by immunological technology or measuring biological activity. The above methods can be used singly or in combination.
  • the probe used for hybridization is homologous to any part of the polynucleotide of the present invention, and its length is at least 10 nucleotides, preferably at least 30 nucleotides, more preferably At least 50 nucleotides, preferably at least 100 nucleotides.
  • the length of the probe is usually within 2000 nucleotides, preferably within 1000 nucleotides.
  • the probe used here is generally a DNA sequence chemically synthesized based on the gene sequence information of the present invention.
  • the genes or fragments of the present invention can of course be used as probes.
  • DNA probes can be labeled with radioisotopes, luciferin, or enzymes (such as alkaline phosphatase).
  • immunological techniques such as Western blotting, radioimmunoprecipitation, and enzyme-linked immunosorbent assay (ELISA) can be used to detect the protein product expressed by the human transcription factor LCR-F112. 1 gene expression protein.
  • ELISA enzyme-linked immunosorbent assay
  • a method (Sa iki, et al. Science 1985; 230: 1 350-1 354) using PCR technology to amplify DNA / RNA is preferably used to obtain the gene of the present invention.
  • the RACE method RACE-Rapid Amplification of cDNA Ends
  • the primers used for PCR can be appropriately based on the polynucleotide sequence information of the present invention disclosed herein Select and synthesize using conventional methods.
  • the amplified DM / RNA fragment can be isolated and purified by conventional methods such as by gel electrophoresis.
  • polynucleotide sequence of the gene of the present invention or various DNA fragments and the like obtained as described above can be measured by a conventional method such as dideoxy chain termination method (Sanger et al. PNAS, 1977, 74: 5463-5467). Such polynucleotide sequences can also be determined using commercial sequencing kits and the like. In order to obtain the full-length cDM sequence, sequencing needs to be repeated. Sometimes it is necessary to determine the cDM sequence of multiple clones in order to splice into a full-length cDNA sequence.
  • the present invention also relates to a vector comprising the polynucleotide of the present invention, and a host cell produced by genetic engineering using the vector of the present invention or directly using the human transcription factor LCR-F112. 1 coding sequence, and the recombinant technology to produce the polypeptide of the present invention Methods.
  • a polynucleotide sequence encoding the human transcription factor LCR-F112.1 can be inserted into a vector to form a recombinant vector containing the polynucleotide of the present invention.
  • vector refers to bacterial plasmids, phages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses, or other vectors well known in the art.
  • Vectors suitable for use in the present invention include, but are not limited to: T7 promoter-based expression vectors (Rosenberg, et al.
  • any plasmid and vector can be used to construct a recombinant expression vector.
  • An important feature of expression vectors is that they usually contain an origin of replication, a promoter, a marker gene, and translational regulatory elements.
  • DM sequence can be operably linked to an appropriate promoter in an expression vector to guide mRM synthesis.
  • promoters are: the lac or trp promoter of E.
  • the expression vector also includes a ribosome binding site for translation initiation, a transcription terminator, and the like. Insertion of enhancer sequences into the vector will enhance its transcription in higher eukaryotic cells. Enhancers are cis-acting factors for DNA expression, usually about 10 to 300 base pairs, which act on promoters to enhance gene transcription. Examples include SV40 enhancers of 100 to 270 base pairs on the late side of the origin of replication, polyoma enhancers and adenovirus enhancers on the late side of the origin of replication.
  • the expression vector preferably contains one or more selectable marker genes to provide phenotypic traits for selection of transformed host cells, such as dihydrofolate reductase, neomycin resistance, and green for eukaryotic cell culture.
  • selectable marker genes to provide phenotypic traits for selection of transformed host cells, such as dihydrofolate reductase, neomycin resistance, and green for eukaryotic cell culture.
  • GFP fluorescent protein
  • tetracycline or ampicillin resistance for E. coli.
  • a polynucleotide encoding human transcription factor LCR-F112. 1 or a recombinant vector containing the polynucleotide can be transformed or transduced into a host cell to form a genetically engineered host cell containing the polynucleotide or the recombinant vector.
  • the term "host cell” refers to a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell. Representative examples are: E.
  • coli Streptomyces
  • bacterial cells such as Salmonella typhimurium
  • fungal cells such as yeast
  • plant cells Plague cells such as S2 or Sf9
  • animal cells such as CH0, COS or Bowes melanoma cells.
  • Transformation of a host cell with a DNA sequence described in the present invention or a recombinant vector containing the DNA sequence can be performed using conventional techniques well known to those skilled in the art.
  • the host is a prokaryote such as E. coli
  • Competent cells that absorb DNA can be harvested after the exponential growth phase and treated with the CaCl 2 method, the steps used are well known in the art. Alternatively, MgCl 2 is used.
  • transformation can also be performed by electroporation.
  • the host is a eukaryotic organism, the following DNA transfection methods can be used: calcium phosphate co-precipitation method, or conventional mechanical methods such as microinjection, electroporation, and liposome packaging.
  • the polynucleotide sequence of the present invention can be used to express or produce recombinant human transcription factor LCR-F112. 1 (Science, 1984; 224: 1431). Generally there are the following steps:
  • the medium used in the culture may be selected from various conventional mediums. Culture is performed under conditions suitable for host cell growth. After the host cells have grown to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.
  • a suitable method such as temperature conversion or chemical induction
  • the recombinant polypeptide may be coated in a cell, expressed on a cell membrane, or secreted outside the cell. If necessary, the recombinant protein can be isolated and purified by various separation methods using its physical, chemical and other properties. These methods are well known to those skilled in the art. These methods include, but are not limited to: conventional renaturation treatment, protein precipitant treatment (salting out method), centrifugation, osmotic disruption, ultrasonic treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion Exchange chromatography, high performance liquid chromatography (HPLC), and various other liquid chromatography techniques and combinations of these methods.
  • conventional renaturation treatment protein precipitant treatment (salting out method), centrifugation, osmotic disruption, ultrasonic treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion Exchange chromatography, high performance liquid
  • polypeptides of the present invention as well as antagonists, agonists and inhibitors of the polypeptides, can be directly used in the treatment of diseases, for example, they can treat malignant tumors, adrenal deficiency, skin diseases, various types of inflammation, HIV infection, and immune diseases.
  • Hemoglobin is the main component of red blood cells and is responsible for transporting oxygen and carbon dioxide in the body.
  • Each hemoglobin molecule consists of two identical four subunits and four heme, and hemoglobin without heme becomes globin.
  • the genes of all globin subunits have very similar structures.
  • the composition of subunits of hemoglobin varies at different stages of individual development.
  • the transcription and expression of globin subunits in vivo are regulated by related transcription factors.
  • the transcription factor LCR regulates the transcription and expression of globin ⁇ , ⁇ and ⁇ subunits. It first binds to the chromosome containing the globin P subunit gene, and then strengthens the transcription and expression of globin ⁇ , ⁇ and P subunits. .
  • the transcription factor LCR-Fl is a gene with a structure and function similar to the known transcription factor LCR.
  • the conserved CNC domain in its protein sequence plays an important role in the transcription and expression regulation of globin ⁇ , ⁇ , and ⁇ subunits. It plays an important regulatory role in the formation of globin. Mutation or abnormal expression of this protein will cause abnormal expression of the relevant globin in the body, and then affect the activity of the relevant hemoglobin in the body, which will cause various related diseases.
  • the expression profile of the polypeptide of the present invention is consistent with the expression profile of human transcription factor LCR-F1, both of which have similar biological functions.
  • the polypeptide of the present invention is involved in regulating the transcription and expression of globin ⁇ , ⁇ , and P subunits in vivo, which is of great significance for the normal formation of globin, and abnormal expression of it will cause abnormal formation of red blood cells and related diseases.
  • the abnormal expression of the human transcription factor LCR-F112. 1 of the present invention will produce various diseases, especially red blood cell diseases. These diseases include, but are not limited to:
  • Red blood cell disease various anemias, erythrocytosis, symptomatic erythrocytosis, hereditary oval cell cytosis.
  • polypeptide of the present invention as well as its antagonists, agonists and inhibitors, can be directly used in the treatment of diseases, for example, it can treat various diseases, especially red blood cell diseases and the like.
  • the invention also provides methods for screening compounds to identify agents that increase (agonist) or suppress (antagonist) the human transcription factor LCR-F112.1.
  • Agonists increase the human transcription factor LCR-F112. 1 to stimulate biological functions such as cell proliferation, while antagonists prevent and treat disorders related to excessive cell proliferation, such as various cancers.
  • a mammalian cell or a membrane preparation expressing human transcription factor LCR-F112. 1 can be cultured together with a labeled human transcription factor LCR-F112. 1 in the presence of a drug. The ability of the drug to increase or block this interaction is then determined.
  • Antagonists of human transcription factor LCR-F112. 1 include antibodies, compounds, receptor deletions, and the like that have been screened.
  • the antagonist of human transcription factor LCR-F112. 1 can bind to human transcription factor LCR-F112. 1 and eliminate its function, or inhibit the production of the polypeptide, or bind to the active site of the polypeptide so that the polypeptide cannot function. biological functions.
  • the human transcription factor LCR-F112. 1 When screening compounds as antagonists, the human transcription factor LCR-F112. 1 can be added to a bioanalytical assay, and the compound can be determined by measuring the effect of the compound on the interaction between the human transcription factor LCR-F112. 1 and its receptor. Whether it is an antagonist. Receptor deletions and analogs that act as antagonists can be screened in the same way as for screening compounds described above. Polypeptide molecules capable of binding to human transcription factor LCR-F112. 1 can be obtained by screening a random peptide library composed of various possible combinations of amino acids bound to a solid phase. When screening, the human transcription factor LCR-F112. 1 molecule should generally be labeled.
  • the present invention provides polypeptides, and fragments, derivatives, analogs or cells thereof as antigens. To produce antibodies. These antibodies can be polyclonal or monoclonal antibodies. The invention also provides antibodies against the human transcription factor LCR-F112. 1 epitope. These antibodies include (but are not limited to): polyclonal antibodies, monoclonal antibodies, chimeric antibodies, single chain antibodies, Fab fragments, and fragments produced by Fab expression libraries.
  • Polyclonal antibodies can be produced using human transcription factor LCR-F112. 1 by direct injection of immunized animals (such as rabbits, mice, rats, etc.).
  • immunized animals such as rabbits, mice, rats, etc.
  • adjuvants can be used to enhance the immune response, including but not limited to Freund's Adjuvant, etc.
  • Techniques for preparing monoclonal antibodies to human transcription factor LCR-F112. 1 include, but are not limited to, hybridoma technology (Kohler and Mistein. Nature, 1975, 256: 495-497), triple tumor technology, human beta-cell hybridoma Technology, EBV-hybridoma technology, etc.
  • Chimeric antibodies that bind human constant regions and non-human-derived variable regions can be produced using existing techniques (Morrison et al, PMS, 1985, 81: 6851).
  • the existing technology for producing single chain antibodies (U.S. Pat No. 4946778) can also be used to produce single chain antibodies against the human transcription factor LCR-F112.1.
  • Anti-human transcription factor LCR-F112. 1 antibody can be used in immunohistochemistry to detect human transcription factor LCR-F112. 1 in biopsy specimens.
  • Monoclonal antibodies that bind to human transcription factor LCR-F112. 1 can also be labeled with radioisotopes and injected into the body to track their location and distribution. This radiolabeled antibody can be used as a non-invasive diagnostic method to locate tumor cells and determine whether there is metastasis.
  • Antibodies can also be used to design immunotoxins against a specific bead site in the body.
  • human transcription factor LCR-F112. 1 high affinity monoclonal antibodies can covalently bind to bacterial or plant toxins (such as diphtheria toxin, ricin, ormosine, etc.).
  • a common method is to attack the amino group of an antibody with a thiol cross-linking agent such as SPDP and bind the toxin to the antibody through the exchange of disulfide bonds.
  • This hybrid antibody can be used to kill the human transcription factor LCR-F112. 1 positive Cell.
  • the antibodies of the present invention can be used to treat or prevent diseases related to the human transcription factor LCR-F112.1.
  • Administration of an appropriate dose of the antibody can stimulate or block the production or activity of the human transcription factor LCR-F112.1.
  • the present invention also relates to a diagnostic test method for quantitatively and locally detecting the level of human transcription factor LCR-F112.1.
  • tests are well known in the art and include FISH assays and radioimmunoassays.
  • the level of human transcription factor LCR-F112.1 detected in the test can be used to explain the importance of human transcription factor LCR-F112. 1 in various diseases and to diagnose the role of human transcription factor LCR-F112. 1 disease.
  • polypeptide of the present invention can also be used for peptide mapping analysis.
  • the polypeptide can be specifically cleaved by physical, chemical or enzymatic analysis, and subjected to one-dimensional or two-dimensional or three-dimensional gel electrophoresis analysis, and more preferably mass spectrometry analysis.
  • the polynucleotide encoding the human transcription factor LCR-F112. 1 can also be used for a variety of therapeutic purposes. Genetic Therapeutic techniques can be used to treat abnormal cell proliferation, development, or metabolism caused by the non-expression or abnormal / inactive expression of the human transcription factor LCR-F112.1.
  • Recombinant gene therapy vectors (such as viral vectors) can be designed to express mutated human transcription factor LCR-F112. 1 to inhibit endogenous human transcription factor LCR-F112. 1 activity.
  • a variant human transcription factor LCR-F112. 1 may be a shortened human transcription factor LCR-F1 12.1 that lacks a signaling functional domain, and although it can bind to downstream substrates, it lacks signaling activity .
  • the recombinant gene therapy vector can be used to treat diseases caused by abnormal expression or activity of human transcription factor LCR-F112.1.
  • Virus-derived expression vectors such as retrovirus, adenovirus, adenovirus-associated virus, herpes simplex virus, parvovirus, etc. can be used to transfer a polynucleotide encoding the human transcription factor LCR-F112. 1 into a cell.
  • a method for constructing a recombinant viral vector carrying a polynucleotide encoding the human transcription factor LCR-F112. 1 can be found in existing literature (Sarabrook, eta l.).
  • a recombinant polynucleotide encoding the human transcription factor LCR-F112.1 can be packaged into liposomes and transferred into cells.
  • Methods for introducing a polynucleotide into a tissue or cell include: directly injecting the polynucleotide into a tissue in vivo; or introducing the polynucleotide into a cell in vitro through a vector (such as a virus, phage, or plasmid), and then transplanting the cell Into the body and so on.
  • a vector such as a virus, phage, or plasmid
  • Oligonucleotides including antisense RNA and DNA
  • ribozymes that inhibit human transcription factor LCR-F112. 1 mRNA are also within the scope of the present invention.
  • a ribozyme is an enzyme-like RNA molecule that specifically decomposes a specific MA. Its mechanism of action is that the ribozyme molecule specifically hybridizes with a complementary target RNA for endonucleation.
  • Antisense RNA, DNA, and ribozymes can be obtained using any existing RNA or DNA synthesis technology, such as solid-phase phosphoramidite chemical synthesis to synthesize oligonucleotides.
  • Antisense MA molecules can be obtained by in vitro or in vivo transcription of a DNA sequence encoding the RNA.
  • This DNA sequence has been integrated downstream of the vector's RNA polymerase promoter.
  • it can be modified in a variety of ways, such as increasing the sequence length on both sides, and the linkage between ribonucleosides using phosphate thioester or peptide bonds instead of phosphodiester bonds. '
  • the polynucleotide encoding human transcription factor LCR-F112. 1 can be used for the diagnosis of diseases related to human transcription factor LCR-F112. 1.
  • the polynucleotide encoding human transcription factor LCR-F112. 1 can be used to detect the expression of human transcription factor LCR-F112. 1 or the abnormal expression of human transcription factor LCR-F112. 1 in a disease state.
  • the DNA sequence encoding human transcription factor LCR-F1 12.1 can be used to hybridize biopsy specimens to determine the expression status of human transcription factor LCR-F112.1.
  • Hybridization techniques include Southern blotting, Nor thern blotting, and in situ hybridization. These techniques and methods are publicly available and mature, and related kits are commercially available.
  • polynucleotides of the present invention can be used as probes to be fixed on a microarray or a DNA chip (also referred to as a "gene chip") for analyzing differential expression analysis and gene diagnosis of genes in tissue.
  • a microarray or a DNA chip also referred to as a "gene chip”
  • RNA-polymerase chain reaction RT-PCR
  • RT-PCR RNA-polymerase chain reaction
  • Human transcription factor LCR-F112. 1 gene can also be used to diagnose human transcription factor LCR-F112. 1 related diseases.
  • Human transcription factor LCR-F112. 1 mutations include point mutations, translocations, deletions, recombinations, and any other abnormalities compared to the normal wild-type human transcription factor LCR-F112. 1 DNA sequence. Mutations can be detected using existing techniques such as Southern blotting, DNA sequence analysis, PCR and in situ hybridization. In addition, mutations may affect protein expression. Therefore, Nor thern blotting and Western blotting can be used to indirectly determine whether a gene is mutated.
  • sequences of the invention are also valuable for chromosome identification. This sequence will specifically target a specific position on a human chromosome and can hybridize to it. Currently, specific sites for each gene on the chromosome need to be identified. Currently, only a few chromosome markers based on actual sequence data (repeating polymorphisms) are available for marking chromosome positions. According to the present invention, in order to associate these sequences with disease-related genes, an important first step is to locate these DNA sequences on a chromosome.
  • PCR primers (preferably 15-35bp) are prepared based on cDNA, and the sequences can be mapped on chromosomes. These primers were then used for PCR screening of somatic hybrid cells containing individual human chromosomes. Only those hybrid cells that contain the human gene corresponding to the primer will produce amplified fragments.
  • PCR localization of somatic hybrid cells is a quick way to localize DNA to specific chromosomes.
  • oligonucleotide primers of the present invention in a similar manner, a set of fragments from a specific chromosome or a large number of genomic clones can be used to achieve sublocalization.
  • Other similar strategies that can be used for chromosomal localization include in situ hybridization, chromosome pre-screening with labeled flow sorting, and pre-selection of hybridization to construct chromosome-specific cDNA libraries.
  • Fluorescent in situ hybridization of cDNA clones with metaphase chromosomes allows precise chromosomal localization in one step.
  • FISH Fluorescent in situ hybridization
  • the differences in cDNA or genomic sequences between the affected and unaffected individuals need to be determined. If a mutation is observed in some or all diseased individuals and the mutation is not observed in any normal individuals, the mutation may be the cause of the disease. Comparing affected and unaffected individuals usually involves first looking for staining Structural changes in the body, such as deletions or translocations that are visible from the chromosomal level or detectable with cDNA sequence-based PCR. According to the resolution capabilities of current physical mapping and gene mapping technology, the cDNA accurately mapped to the chromosomal region associated with the disease can be one of 50 to 500 potentially pathogenic genes (assuming 1 megabase mapping resolution) Capacity and each 20kb corresponds to a gene).
  • the polypeptides, polynucleotides and mimetics, agonists, antagonists and inhibitors of the present invention can be used in combination with a suitable pharmaceutical carrier.
  • suitable pharmaceutical carrier can be water, glucose, ethanol, salts, buffers, glycerol, and combinations thereof.
  • the composition comprises a safe and effective amount of the polypeptide or antagonist, and carriers and excipients which do not affect the effect of the drug. These compositions can be used as drugs for the treatment of diseases.
  • the invention also provides a kit or kit containing one or more containers containing one or more ingredients of the pharmaceutical composition of the invention.
  • a kit or kit containing one or more containers containing one or more ingredients of the pharmaceutical composition of the invention.
  • these containers there may be instructional instructions given by government agencies that manufacture, use, or sell pharmaceuticals or biological products, which prompts permission for administration on the human body by government agencies that produce, use, or sell.
  • the polypeptides of the invention can be used in combination with other therapeutic compounds.
  • the pharmaceutical composition can be administered in a convenient manner, such as by a topical, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal route of administration.
  • Human transcription factor LCR-F112. 1 is administered in an amount effective to treat and / or prevent a specific indication.
  • the amount and range of human transcription factor LCR-F112. 1 administered to a patient will depend on many factors, such as the mode of administration, the health conditions of the person to be treated, and the judgment of the diagnostician. Examples
  • Total human fetal brain RNA was extracted by one-step method with guanidine isothiocyanate / phenol / chloroform.
  • Poly (A) mRNA was isolated from total RNA using Quik mRNA Isolat ion Kit (product of Qiegene). 2ug poly (A) mRNA is reverse transcribed to form cDNA.
  • the Smart cDM cloning kit purchased from Clontech was used to insert the 00 fragment into the multi-cloning site of the pBSK (+) vector (Clontech) to transform DH5 ⁇ to form a CDM library.
  • Dye terminate cycle react ion sequencing kit Perkin-Elmer
  • ABI 377 automatic sequencer Perkin-Elmer
  • CDNA The sequence was compared with the existing public DM sequence database (Genebank), and the cDNA sequence of one of the clones 0080c05 was found to be a new DNA.
  • a series of primers were synthesized to determine the inserted cDNA fragments of the clone in both directions.
  • CDNA was synthesized using fetal brain cell total MA as a template and oligo-dT as a primer for reverse transcription reaction. After purification with Qiagene's kit, PCR was performed with the following primers:
  • Primer2 5'- TTCATAGCAGCTTTATTCATAACA -3 '(SEQ ID NO: 4)
  • Primerl is a forward sequence starting at lbp of the 5th end of SEQ ID NO: 1;
  • Primer2 is the 3, terminal reverse sequence of SEQ ID NO: 1.
  • Amplification conditions 50 ⁇ l reaction volume containing 50 mmol / LKCl, 10 mmol / L Tr is-HCl pH 8.5, 1.5 mmol / L MgCl 2 , 200 mol / L dNTP, lOpmol primers, 1 ⁇ Taq DNA polymerase (Clontech).
  • the reaction was performed on a PE9600 DNA thermal cycler (Perkin-Elmer) for 25 cycles under the following conditions: 94 ° C 30sec; 55. C 30sec; 72 ° C 2min.
  • ⁇ -act in was set as a positive control and template blank was set as a negative control.
  • the amplified product was purified using a QIAGEN kit and ligated to a pCR vector (Invitrogen product) using a TA cloning kit.
  • the DNA sequence analysis results showed that the DM sequence of the PCR product was exactly the same as 1-1474bp shown in SEQ ID NO: 1.
  • Example 3 Northern blot analysis of human transcription factor LCR-F112.1 gene expression Total RNA extraction in one step [Anal. Biochem 1987, 162, 156-159] 0 This method involves acid guanidinium thiocyanate-chloroform extraction .
  • the tissue is homogenized with 4M guanidine isothiocyanate-25mM sodium citrate, 0.2M sodium acetate (pH4.0), and 1 time volume of phenol and 1/5 volume of chloroform-isoamyl alcohol (49: 1 ), Mix and centrifuge.
  • the aqueous layer was aspirated, isopropanol (0.8 vol) was added and the mixture was centrifuged to obtain RM precipitate.
  • the resulting RNA pellet was washed with 70% ethanol, dried and dissolved in water.
  • Electrophoresis was performed on a 1.2% agarose gel containing 2 g of RNA on 20 mM 3- (N-morpholino) propanesulfonic acid (H7.0)-5 mM sodium acetate-ImM EDTA-2.2M formaldehyde. Then Transfer to a nitrocellulose membrane. A- 32 P dATP was used to prepare 32 P-labeled DM probes by random primers.
  • the DNA probe used was the PCR amplified human transcription factor LCR-F112 shown in Figure 1. 1 coding region sequence (968bp to 1300bp).
  • a 32P-labeled probe (approximately 2 x 10 6 cpm / ml) and a nitrate
  • the cellulose acetate membrane was hybridized overnight at 42 ° C in a solution containing 50% formamide-25mM KH 2 P0 4 ( ⁇ 7.4) -5 ⁇ SSC-5 ⁇ Denhardt's solution and 20 ( ⁇ g / ml salmon Sperm DNA. After hybridization, the filter was washed in 1 X SSC-0.1% SDS at 55 ° C for 30 min. Then, it was analyzed and quantified using a Phosphor Imager.
  • Example 4 In vitro expression of recombinant human transcription factor LCR-F112.1 , Separation and purification
  • Primer 3 5 '-CCCCATATGATGCATCACCACACCCAGCTAATT-3' (Seq ID No: 5)
  • Primer4 5'-CATGGATCCTTACATTAAGTGAAAGAAGCTGGA-3 '(Seq ID No: 6)
  • the 5' ends of these two primers contain Mel and BamHI restriction sites, respectively , followeded by the coding sequences of the 5 'and 3' ends of the gene of interest, respectively, and the Ndel and BamHI restriction sites correspond to the selectivity on the expression vector plasmid pET-28b (+) (Novagen, Cat. No. 69865.3) Endonuclease site.
  • the PCR reaction was performed using the pBS-0080c05 plasmid containing the full-length target gene as a template.
  • the PCR reaction conditions were as follows: a total volume of 50 ⁇ 1 containing 10 pg of pBS-0080c05 plasmid, primers Primer-3 and Primer-4, and j was lOpmol, Advantage polymerase Mix (Clontech) 1 ⁇ 1. Cycle parameters: 94 ° C 20s, 60 ° C 30s, 68 ° C 2 min, a total of 25 cycles. Ndel and BamHI were used to double digest the amplified product and plasmid pET-28 (+), respectively, and large fragments were recovered and ligated with T4 ligase.
  • the ligation product was transformed into E. coli DH5a by the calcium chloride method. After being cultured overnight on LB plates containing kanamycin (final concentration 30 g / ml), positive clones were selected by colony PCR method and sequenced. A positive clone (PET-0080c05) with the correct sequence was selected, and the recombinant plasmid was transformed into E. coli BL21 (DE3) plySs (product of Novagen) using the calcium chloride method. In containing kanamycin (final concentration of 30 ⁇ ⁇ / ⁇ 1) in LB liquid medium, host strain BL21 (P ET-0080c05) at 37. C.
  • the following peptides specific to human transcription factor LCR-F112.1 were synthesized using a peptide synthesizer (product of PE company): NH2-Met-His-His-His-Thr-Gln-Leu-Ile-Ser-Val-Phe-Phe -Val-Glu-Thr-C00H (SEQ ID NO: 7).
  • the polypeptide is coupled with hemocyanin and bovine serum albumin to form a complex, respectively. See: Avrameas, et al. Immunochemis try, 1969; 6:43.
  • the suitable oligonucleotide fragments selected from the polynucleotides of the present invention are used as hybridization probes in various aspects.
  • the probes can be used to hybridize to the genome or CDM library of normal tissue or pathological tissue from different sources to It is determined whether it contains the polynucleotide sequence of the present invention and a homologous polynucleotide sequence is detected.
  • the probe can be used to detect the polynucleotide sequence of the present invention or its homologous polynucleotide sequence in normal tissues or Whether the expression in tissue cells is abnormal.
  • the purpose of this embodiment is to select a suitable oligonucleotide fragment from the polynucleotide SEQ ID NO: 1 of the present invention as a hybridization probe, and to identify whether some tissues contain the polynucleoside of the present invention by a filter hybridization method Acid sequence or a homologous polynucleotide sequence thereof.
  • Filter hybridization methods include dot blotting, Southern imprinting, Northern blotting, and copying methods. They all use the same steps to immobilize the polynucleotide sample to be tested on the filter.
  • the sample-immobilized filter is first pre-hybridized with a probe-free hybridization buffer to saturate the non-specific binding site of the sample on the filter with the carrier and the synthesized polymer.
  • the pre-hybridization solution is then replaced with a hybridization buffer containing labeled probes and incubated to hybridize the probes to the target nucleic acid.
  • the unhybridized probes are removed by a series of membrane washing steps.
  • This embodiment uses higher-intensity washing conditions (such as lower salt concentration and higher temperature), so that the hybridization background is reduced and only strong specific signals are retained.
  • the probes used in this embodiment include two types: the first type of probes are oligonucleotide fragments that are completely the same as or complementary to the polynucleotide SEQ ID NO: 1 of the present invention; the second type of probes are partially related to the present invention
  • the polynucleotide SEQ ID NO: 1 is the same or complementary oligonucleotide fragment.
  • the dot blot method is used to fix the sample on the filter membrane. Under the high-intensity washing conditions, the first type of probe and the sample have the strongest hybridization specificity and are retained.
  • oligonucleotide fragments from the polynucleotide SEQ ID NO: 1 of the present invention for use as hybridization probes should follow the following principles and several aspects to be considered:
  • the preferred range of probe size is 18-50 nucleotides; 2, GC content is 30% -70%, non-specific hybridization increases when it exceeds;
  • Those that meet the above conditions can be used as primary selection probes, and then further computer sequence analysis, including the primary selection probe and its source sequence region (ie, SEQ ID NO: 1) and other known genomic sequences and their complements The regions are compared for homology. If the homology with the non-target molecular region is greater than 85% or there are more than 15 consecutive bases, then the primary probe should not be used;
  • Probe 1 which belongs to the first type of probe, is completely homologous or complementary to the gene fragment of SEQ ID NO: 1 (41Nt):
  • Probe 2 which belongs to the second type of probe, is equivalent to the replacement mutation sequence (41Nt) of the gene fragment or its complementary fragment of SEQ ID NO: 1:
  • PBS phosphate buffered saline
  • step 8-13 are only used when contamination must be removed, otherwise step 14 can be performed directly.
  • NC membranes nitrocellulose membranes
  • Two NC membranes are required for each probe for subsequent experiments.
  • the film is washed with high-strength conditions and strength conditions, respectively.
  • the 32 P-Probe (the second peak is free ⁇ - 32 P-dATP) is prepared.
  • the sample membrane was placed in a plastic bag, and 3-lOmg pre-hybridization solution (lOxDenhardt-s; 6xSSC, 0.1 mg / ml CT DNA (calf thymus DM)) was added. After sealing the mouth of the bag, shake at 68 ° C for 2 hours.
  • 3-lOmg pre-hybridization solution lOxDenhardt-s; 6xSSC, 0.1 mg / ml CT DNA (calf thymus DM)
  • Gene microarrays or DNA microarrays are new technologies currently being developed by many national laboratories and large pharmaceutical companies. It refers to the orderly and high-density arrangement of a large number of target gene fragments on glass, The data is compared and analyzed on a carrier such as silicon using fluorescence detection and computer software to achieve the purpose of rapid, efficient, and high-throughput analysis of biological information.
  • the polynucleotide of the present invention can be used as target DNA for gene chip technology for high-throughput research of new gene functions; search for and screen new tissue-specific genes, especially new genes related to diseases such as tumors; diagnosis of diseases such as hereditary diseases . The specific method steps have been reported in the literature.
  • a total of 4,000 polynucleotide sequences of various full-length cDNAs are used as the target DM, including the polynucleotide of the present invention. They were respectively amplified by PCR, and the concentration of the amplified product was adjusted to about 500ng / ul after purification.
  • the spots were spotted on a glass medium with a Cartesian 7500 spotter (purchased from Cartesian Company, USA). The distance between them is 280 ⁇ m.
  • the spotted slides were hydrated and dried, cross-linked in a UV cross-linker, and dried after elution to fix the DNA on the glass slides to prepare chips.
  • the specific method steps have been reported in the literature.
  • the sample post-processing steps in this embodiment are:
  • the probes from the above two tissues and the chip were respectively hybridized in a UniHyb TM Hybridizat ion Solution (purchased from TeleChem) hybridization solution for 16 hours, washed with a washing solution (lx SSC, 0.23 ⁇ 4SDS) at room temperature, and then scanned with ScanArray.
  • a 3000 scanner purchased from General Scanning, USA was used for scanning. The scanned images were analyzed and processed with Imagene software (Biodiscovery, USA) to calculate the Cy3 / Cy5 ratio of each point.
  • the above specific tissues are fetal brain, bladder mucosa, PMA + Ecv304 cell line, LPS + Ecv304 cell line thymus, normal fibroblasts 1024NC, Fibroblas t, growth factor stimulation, 1024NT, scar formation fc growth factor stimulation, 1013HT, scar into fc without growth factor stimulation, 1 G13HC, bladder cancer plant cell EJ, bladder cancer, bladder cancer, liver cancer, liver cancer cell line, fetal skin, spleen, prostate cancer, jejunal adenocarcinoma Cardiac cancer. Based on these 18 Cy3 / Cy5 ratios, a bar graph is drawn (Figure 1). The figure shows the expression of human transcription factor LCR-F112. 1 and human transcription factor LCR-F1 according to the present invention.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Description

一种新的多肽——人转彔因子 LCR-F112. 1和编码这种多肽的多核苷酸 拮术领域
本发明属于生物技术领域， 具体地说， 本发明描述了一种新的多肽 ~~ Λ 转录因子 LCR-F112. 1， 以及编码此多肽的多核苷酸序列。 本发明还涉及此多 核苷酸和多肽的制备方法和应用。 技术背景
血红蛋白是脊髓动物红血球的主要组成成分， 其在生物体内负责运送氧气 和二氧化碳。 每个血红蛋白分子由两个相同的四个亚基和四个血红素组成， 不 含血红素的血红蛋白成为珠蛋白。 所有的珠蛋白亚基的基因都有十分相似的结 构， 在个体发育的不同阶段， 血红蛋白的亚基组成各不相同。 珠蛋白亚基在体 内的转录与表达受相关转录因子的调控。 转录因子 LCR 即在生物体内调控着珠 蛋白 Υ、 ε及 P亚基的转录与表达， 其在生物体内具有两个重要的作用活性， 首先是与含珠蛋白 Ρ亚基基因的染色体结合， 然后再加强珠蛋白 ε、 γ及 β亚 基的转录及表达。 由此可见， 该转录因子在珠蛋白的转录表达过程中起着重要 的调控作用， 其突变或表达异常将导致体内相关珠蛋白的表达异常， 进而影响 相关血红蛋白的表达及作用异常， 从而引发各种相关的疾病。
1994年， John等人又从人中克隆得到了一新的转录因子 LCR-F1 , 并对该 蛋白的结构及功能进行了研究。 该蛋白与已知的转录因子 LCR相似， 其蛋白序 列中亦含有保守的 CNC结构域， 该结构域可能在蛋白的转录调控过程中起重要 的调节作用。 该蛋白在生物体内亦与珠蛋白 β亚基基因结合， 并调控着珠蛋白 ε、 γ及 Ρ亚基的转录及表达。 其在体内珠蛋白的形成过程中起着重要'的调节 作用。 该蛋白的突变或表达异常将导致体内相关珠蛋白的表达异常， 进而影响 相关血红蛋白在体内的作用活性， 即引发各种相关的疾病 [John J. Cater ina, David Donze et al. , 1994, uc leic Acids Research, 22 (12) : 2383-2391]。
由上可知， 转录因子 LCR-F1 在体内珠蛋白的形成过程中起着极为重要的 作用。 该蛋白的突变或表达异常将导致体内相关血红蛋白的形成异常， 进而影 响各种相关的代谢途径的发生。 其在生物体内通常与各种相关的呼吸代谢紊乱 性疾病及相关的物质代谢紊乱性疾病的发生密切相关。 其还可用于诊断及治疗 上述各种相关的疾病。
通过基因芯片的分析发现， 在膀胱粘膜、 PMA+的 Ecv304 细胞株、 LPS+的 Ecv304 细胞株胸腺、 正常成纤维细胞 1 024NC、 Fibrob l a s t , 生长因子刺激， 1024NT, 疤痕成 fc 生长因子刺激， 101 3HT、 疤痕成 fc 未用生长因子刺激， 101 3HC, 膀胱癌建株细胞 EJ、 膀胱癌旁、 膀胱癌、 肝癌、 肝癌细胞株、 胎皮、 脾脏、 前列腺癌、 空肠腺癌、 贲门癌中， 本发明的多肽的表达谱与人转录因子 LCR-F1 的表达谱非常近似， 因此二者功能也可能类似。 本发明被命名为人转 录因子 LCR-F112. 1。
由于如上所述人转录因子 LCR- F112. 1 蛋白在调节细胞分裂和胚胎发育等 机体重要功能中起重要作用， 而且相信这些调节过程中涉及大量的蛋白， 因而 本领域中一直需要鉴定更多参与这些过程的人转录因子 LCR- F112. 1 蛋白， 特 别是鉴定这种蛋白的氨基酸序列。 新人转录因子 LCR-F112. 1 蛋白编码基因的 分离也为研究确定该蛋白在健康和疾病状态下的作用提供了基础。 这种蛋白可 能构成开发疾病诊断和 /或治疗药的基础， 因此分离其编码 DNA是非常重要的。 发明目的
本发明的一个目的是提供分离的新的多肽一人转录因子 LCR- F112. 1 以 及其片段、 类似物和衍生物。
本发明的另一个目的是提供编码该多肽的多核苷酸。
本发明的另一个目的是提供含有编码人转录因子 LCR-F112. 1 的多核苷酸 的重组载体。
本发明的另一个目的是提供含有编码人转录因子 LCR - F112. 1 的多核苷酸 的基因工程化宿主细胞。
本发明的另一个目的是提供生产人转录因子 LCR-F112. 1的方法。
本发明的另一个目的是提供针对本发明的多肽——人转录因子 LCR-F112. 1 的抗体。
本发明的另一个目的是提供了针对本发明多肽一人转录因子 LCR-F112. 1 的模拟化合物、 拮抗剂、 激动剂、 抑制剂。
本发明的另一个目的是提供诊断治疗与人转录因子 LCR-F112. 1 异常相关 的疾病的方法。 发明概要
本发明涉及一种分离的多肽， 该多肽是人源的， 它包含： 具有 SEQ ID No. 2 氨基酸序列的多肽、 或其保守性变体、 生物活性片段或衍生物。 较佳地， 该 多肽是具有 SEQ ID NO: 2氨基酸序列的多肽。
本发明还涉及一种分离的多核苷酸， 它包含选自下组的一种核苷酸序列或 其变体：
(a)编码具有 SEQ ID No. 2氨基酸序列的多肽的多核苷酸；
(b)与多核苷酸（a)互补的多核苷酸；
(c)与（a)或（b)的多核苷酸序列具有至少 70%相同性的多核苷酸。
更佳地， 该多核苷酸的序列是选自下组的一种： （a)具有 SEQ ID NO: 1 中 968-1300位的序列； 和（b)具有 SEQ ID NO: 1中 1-1474位的序列。
本发明另外涉及一种含有本发明多核苷酸的载体， 特别是表达载体； 一种 用该载体遗传工程化的宿主细胞， 包括转化、 转导或转染的宿主细胞； 一种包 括培养所述宿主细胞和回收表达产物的制备本发明多肽的方法。
本发明还涉及一种能与本发明多肽特异性结合的抗体。
本发明还涉及一种筛选的模拟、 激活、 拮抗或抑制人转录因子 LCR- F112. 1 蛋白活性的化合物的方法， 其包括利用本发明的多肽。 本发明还涉及用该方法 获得的化合物。
本发明还涉及一种体外检测与人转录因子 LCR- F112. 1 蛋白异常表达相关的 疾病或疾病易感性的方法， 包括检测生物样品中所述多肽或其编码多核苷酸序列 中的突变， 或者检测生物样品中本发明多肽的量或生物活性。
本发明也涉及一种药物组合物， 它含有本发明多肽或其模拟物、 激活剂、 拮 抗剂或抑制剂以及药学上可接受的载体。
本发明还涉及本发明的多肽和 /或多核苷酸在制备用于治疗癌症、 发育性 疾病或免疫性疾病或其它由于人转录因子 LCR- F112. 1 表达异常所引起疾病的 药物的用途。
本发明的其它方面由于本文的技术的公开， 对本领域的技术人员而言是显而 易见的。 附图说明
下列附图用于说明本发明的具体实施方案， 而不用于限定由权利要求书所 界定的本发明范围。
图 1是本发明人转录因子 LCR-F112. 1和人转录因子 LCR- F1的基因芯片表达谱比 较图。 上图是人转录因子 LCR-FlU. l的表达谱折方图， 下图是人转录因子 LCR-F1 的表达谱折方图。 其中， 1-胎脑、 2-膀胱粘膜、 3-PMA+的 Ecv304细胞株、 4-LPS+ 的 Ecv3G4细胞株胸腺、 5 -正常成纤维细胞 1024NC、 6- Fibroblas t , 生长因子刺激， 1024NT、 7-疤痕成 fc生长因子刺激， 1013HT、 8-疤痕成 fc未用生长因子刺激， 1013HC、 9-膀胱癌建株细胞 EJ、 10-膀胱癌旁、 11-膀胱癌、 12-肝癌、 13-肝癌细 胞株、 14-胎皮、 15-脾脏、 16-前列腺癌、 17-空肠腺癌、 18贲门癌。
图 2 为分离的人转录因子 LCR- F112. 1 的聚丙烯酰胺凝胶电泳图 （ SDS- PAGE ) 。 12kDa为蛋白质的分子量。 箭头所指为分离出的蛋白条带。 发明内容
本说明书和杈利要求书中使用的下列术语除非特别说明具有如下的含义： "核酸序列" 是指寡核苷酸、 核苷酸或多核苷酸及其片段或部分， 也可以 指基因组或合成的 DM或 RNA, 它们可以是单链或双链的， 代表有义链或反义链。 类似地， 术语 "氨基酸序列" 是指寡肽、 肽、 多肽或蛋白质序列及其片段或部 分。 当本发明中的 "氨基酸序列" 涉及一种天然存在的蛋白质分子的氨基酸序 列时， 这种 "多肽" 或 "蛋白质" 不意味着将氨基酸序列限制为与所述蛋白质 分子相关的完整的天然氨基酸。
蛋白质或多核苷酸 "变体" 是指一种具有一个或多个氨基酸或核苷酸改 变的氨基酸序列或编码它的多核苷酸序列。 所述改变可包括氨基酸序列或核苷 酸序列中氨基酸或核苷酸的缺失、 插入或替换。 变体可具有 "保守性" 改变， 其中替换的氨基酸具有与原氨基酸相类似的结构或化学性质， 如用亮氨酸替换 异亮氨酸。 变体也可具有非保守性改变， 如用色氨酸替换甘氨酸。
"缺失" 是指在氨基酸序列或核苷酸序列中一个或多个氨基酸或核苷酸的 缺失。
"插入" 或 "添加" 是指在氨基酸序列或核苷酸序列中的改变导致与天然存 在的分子相比， 一个或多个氨基酸或核苷酸的增加。 "替换" 是指由不同的氨基酸' 或核苷酸替换一个或多个氨基酸或核苷酸。
"生物活性" 是指具有天然分子的结构、 调控或生物化学功能的蛋白质。 类 似地， 术语 "免疫学活性" 是指天然的、 重组的或合成蛋白质及其片段在合适的 动物或细胞中诱导特定免疫反应以及与特异性抗体结合的能力。
"激动剂" 是指当与人转录因子 LCR - F112. 1结合时， 一种可引起该蛋白质 改变从而调节该蛋白质活性的分子。 激动剂可以包括蛋白质、 核酸、 碳水化合 物或任何其它可结合人转录因子 LCR-F112. 1的分子。
"拮抗剂" 或 "抑制物" 是指当与人转录因子 LCR- F112. 1结合时， 一种可 封闭或调节人转录因子 LCR- F112. 1的生物学活性或免疫学活性的分子。 拮抗剂 和抑制物可以包括蛋白质、 核酸、 碳水化合物或任何其它可结合人转录因子 LCR-F112. 1的分子。
"调节" 是指人转录因子 LCR-F112. 1的功能发生改变， 包括蛋白质活性的 升高或降低、 结合特性的改变及人转录因子 LCR-F112. 1的任何其它生物学性 质、 功能或免疫性质的改变。
"基本上纯" 是指基本上不含天然与其相关的其它蛋白、 脂类、 糖类或其它 物质。 本领域的技术人员能用标准的蛋白质纯化技术纯化人转录因子 LCR-F112. 1。 基本上纯的人转录因子 LCR-F112. 1在非还原性聚丙烯酰胺凝胶上能产生单一的主 带。 人转录因子 LCR-F112. 1多肽的纯度可用氨基酸序列分析。
"互补的" 或 "互补" 是指在允许的盐浓度和温度条件下通过碱基配对的 多核苷酸天然结合。 例如， 序列 "C-T- G - A" 可与互补的序列 "G- A-C-T" 结合。 两个单链分子之间的互补可以是部分的或全部的。 核酸链之间的互补程度对于 核酸链之间杂交的效率及强度有明显影响。
"同源性" 是指互补的程度， 可以是部分同源或完全同源。 "部分同源" 是指一种部分互补的序列， 其至少可部分抑制完全互补的序列与靶核酸的杂 交。 这种杂交的抑制可通过在严格性程度降低的条件下进行杂交 （Southern印 迹或 Nor thern印迹等） 来检测。 基本上同源的序列或杂交探针可竟争和抑制完 全同源的序列与靶序列在严格性程度降低的条件下的结合。 这并不意味严格性 程度降低的条件允许非特异性结合， 因为严格性程度降低的条件要求两条序列 相互的结合为特异性或选择性相互作用。
"相同性百分率" 是指在两种或多种氨基酸或核酸序列比较中序列相同或 相似的百分率。 可用电子方法测定相同性百分率， 如通过 MEGALIGN程序
( Lasergene sof tware package, DNASTAR, Inc. , Madi son Wi s. ) 。 MEGA GN 程序可根据不同的方法如 Clus ter法比较两种或多种序列（Higg ins, D. G. 和
P. M. Sharp (1988) Gene 73: 237-244) 0 Clus ter法通过检查所有配对之间的 距离将各组序列排列成簇。 然后将各簇以成对或成组分配。 两个氨基酸序列如 序列 A和序列 B之间的相同性百分率通过下式计算：
序列 与序列 S之间匹配的残基个数
序列 ^的残基数一序列 ^中间隔残基数 -序列 3中间隔残基数 X
也可以通过 Clus ter法或用本领域周知的方法如： Totun Hein 测定核酸序列 之间的相同性百分率（Hein L , (1990) Methods in enzyraology 183: 625-645) 0 "相似性" 是指氨基酸序列之间排列对比时相应位置氨基酸残基的相同 或保守性取代的程度。 用于保守性取代的氨基酸， 例如带负电荷的氨基酸可包 括天冬氨酸和谷氨酸； 带正电荷的氨基酸可包括赖氨酸和精氨酸； 具有不带电 荷的头部基团有相似亲水性的氨基酸可包括亮氨酸、 异亮氨酸和缬氨酸； 甘氨 酸和丙氨酸； 天冬酰胺和谷氨酰胺； 丝氨酸和苏氨酸； 苯丙氨酸和酪氨酸。
"反义" 是指与特定的 DNA或 RM序列互补的核苷酸序列。 "反义链" 是指 与 "有义链" 互补的核酸链。
"衍生物" 是指 HFP或编码其核酸的化学修饰物。 这种化学修饰物可以是 用烷基、 酰基或氨基替换氢原子。 核酸衍生物可编码保留天然分子的主要生物 学特性的多肽。
"抗体" 是指完整的抗体分子及其片段， 如 Fa、 ？(^，) 2及? , 其能特异 性结合人转录因子 LCR-F112. 1的抗原决定簇。
"人源化抗体" 是指非抗原结合区域的氨基酸序列被替换变得与人抗体 更为相似， 但仍保留原始结合活性的抗体。
"分离的" 一词指将物质从它原来的环境 （例如， 若是自然产生的就指其 天然环境） 之中移出。 比如说， 一个自然产生的多核苷酸或多肽存在于活动物 中就是没有被分离出来， 但同样的多核苷酸或多肽同一些或全部在自然系统中 与之共存的物质分开就是分离的。 这样的多核苷酸可能是某一载体的一部分， 也可能这样的多核苷酸或多肤是某一组合物的一部分。 既然载体或组合物不是 它天然环境的成分， 它们仍然是分离的。
如本发明所用， "分离的" 是指物质从其原始环境中分离出来 （如果是天 然的物质， 原始环境即是天然环境） 。 如活体细胞内的天然状态下的多聚核苷 酸和多肽是没有分离纯化的， 但同样的多聚核苷酸或多肽如从天然状态中同存 在的其他物质中分开， 则为分离纯化的。
如本文所用 , "分离的人转录因子 LCR-F112. 1"是指人转录因子 LCR-F112. 1 基本上不含天然与其相关的其它蛋白、 脂类、 糖类或其它物质。 本领域的技术 人员能用标准的蛋白质纯化技术纯化人转录因子 LCR-F112. 1。 基本上纯的多肽 在非还原聚丙烯酰胺凝胶上能产生单一的主带'。 人转录因子 LCR-F112. 1 多肽 的纯度能用氨基酸序列分析。
本发明提供了一种新的多肽 ~~ Λ转录因子 LCR-F112. 1， 其基本上是由 SEQ ID NO: 2所示的氨基酸序列组成的。 本发明的多肽可以是重组多肽、 天然多肽、 合成 多肽， 优选重组多肽。 本发明的多肽可以是天然纯化的产物， 或是化学合成的产 物， 或使用重组技术从原核或真核宿主 (例如， 细菌、 酵母、 高等植物、 昆虫和哺 乳动物细胞）中产生。 根据重组生产方案所用的宿主， 本发明的多肽可以是糖基化 的， 或可以是非糖基化的。 本发明的多肽还可包括或不包括起始的甲硫氨酸残基。
本发明还包括人转录因子 LCR-F112. 1的片段、 衍生物和类似物。 如本发 明所用， 术语 "片段" 、 "衍生物" 和 "类似物" 是指基本上保持本发明的人 转录因子 LCR - F112. 1 相同的生物学功能或活性的多肽。 本发明多肽的片段、 衍生物或类似物可以是： （ I ) 这样一种， 其中一个或多个氨基酸残基被保守 或非保守氨基酸残基 （优选的是保守氨基酸残基） 取代， 并且取代的氨基酸可 以是也可以不是由遗传密码子编码的； 或者 （ Π ) 这样一种， 其中一个或多个 氨基酸残基上的某个基团被其它基团取代包含取代基； 或者 （ Π Ι ) 这样一种， 其中成熟多肽与另一种化合物（比如延长多肽半衰期的化合物， 例如聚乙二醇） 融合； 或者 （ IV ) 这样一种， 其中附加的氨基酸序列融合进成熟多肽而形成的 多肽序列 （如前导序列或分泌序列或用来纯化此多肽的序列或蛋白原序列） 。 通过本文的阐述， 这样的片段、 衍生物和类似物被认为在本领域技术人员的知 识范围之内。
本发明提供了分离的核酸 （多核苷酸） ， 基本由编码具有 SEQ ID NO: 2 氨 基酸序列的多肽的多核苷酸组成。 本发明的多核苷酸序列包括 SEQ ID N0: 1 的 核苷酸序列。 本发明的多核苷酸是从人胎脑组织的 cDM 文库中发现的。 它包 含的多核苷酸序列全长为 1474个碱基， 其开放读框 968-1300编码了 110个氨 基酸。 根据基因芯片表达谱比较发现， 此多肽与人转录因子 LCR-F1 有相似的 表达谱， 可推断出该人转录因子 LCR- F112. 1具有人转录因子 LCR-F1相似的功 能。
本发明的多核苷酸可以是 DM形式或是 RNA形式。 DM形式包括 cDM、 基 因组 DM或人工合成的 DNA。 DNA 可以是单链的或是双链的。 DNA 可以是编码 链或非编码链。 编码成熟多肽的编码区序列可以与 SEQ ID NO: 1所示的编码区 序列相同或者是简并的变异体。 如本发明所用， "简并的变异体" 在本发明中 是指编码具有 SEQ ID NO: 2的蛋白质或多肽， 但与 SEQ ID NO: 1所示的编码区 序列有差别的核酸序列。
编码 SEQ ID NO: 2的成熟多肽的多核苷酸包括： 只有成熟多肽的编码序列； 成熟多肽的编码序列和各种附加编码序列； 成熟多肽的编码序列 （和任选的附 加编码序列） 以及非编码序列。
术语 "编码多肽的多核苷酸" 是指包括编码此多肽的多核苷酸和包括附加 编码和 /或非编码序列的多核苷酸。
本发明还涉及上述描述多核苷酸的变异体， 其编码与本发明有相同的氨基 酸序列的多肽或多肽的片断、 类似物和衍生物。 此多核苷酸的变异体可以是天 然发生的等位变异体或非天然发生的变异体。 这些核苷酸变异体包括取代变异 体、 缺失变异体和插入变异体。 如本领域所知的， 等位变异体是一个多核苷酸 的替换形式， 它可能是一个或多个核苷酸的取代、 缺失或插入， 但不会从实质 上改变其编码的多肽的功能。
本发明还涉及与以上所描述的序列杂交的多核苷酸 （两个序列之间具有至 少 50%， 优选具有 70»/。的相同性） 。 本发明特别涉及在严格条件下与本发明所 述多核苷酸可杂交的多核苷酸。 在本发明中， "严格条件" 是指： （1)在较低 离子强度和较高温度下的杂交和洗脱， 如 0. 2xSSC, 0. 1»/»SDS，6(TC ;或（2)杂交 时加用变性剂， 如 50% (v/v)甲酰胺， 0. 1%小牛血清 /0. l%Ficol l , 42 °C等； 或 (3)仅在两条序列之间的相同性至少在 95%以上，更好是 97%以上时才发生杂 交。 并且， 可杂交的多核苷酸编码的多肽与 SEQ ID NO: 2 所示的成熟多肽有 相同的生物学功能和活性。
本发明还涉及与以上所描述的序列杂交的核酸片段。 如本发明所用， "核 酸片段"的长度至少含 10个核苷酸， 较好是至少 20-30个核苷酸， 更好是至少 50 - 60个核苷酸， 最好是至少 100个核苷酸以上。 核酸片段也可用于核酸的扩 增技术（如 PCR)以确定和 /或分离编码人转录因子 LCR- F112. 1的多核苷酸。
本发明中的多肽和多核苷酸优选以分离的形式提供， 更佳地被纯化至均质。 本发明的编码人转录因子 LCR-F112. 1 的特异的多核苷酸序列能用多种方 法获得。 例如， 用本领域熟知的杂交技术分离多核苷酸。 这些技术包括但不局 限于： 1)用探针与基因组或 cDNA 文库杂交以检出同源的多核苷酸序列， 和 2) 表达文库的抗体筛选以检出具有共同结构特征的克隆的多核苷酸片段。
本发明的 DNA片段序列也能用下列方法获得： 1)从基因组 DNA分离双链 DM 序列； 2)化学合成 DM序列以获得所述多肽的双链 DM。
上述提到的方法中， 分离基因组 DNA 最不常 -用。 DNA序列的直接化学合成 是经常选用的方法。 更经常选用的方法是 cDNA序列的分离。 分离感兴趣的 cDNA 的标准方法是从高表达该基因的供体细胞分离 mRNA 并进行逆转录， 形成质粒 或噬菌体 cDM文库。 提取 mRNA的方法已有多种成熟的技术， 试剂盒也可从商 业途径获得（Qiagene)。 而构建 cDNA 文库也是通常的方法（Sambrook, et al.， Molecular Cloning, A Laboratory Manua l, Cold Spr ing Harbor Laboratory. New York, 1989)。还可得到商业供应的 cDNA文库，如 Clontech公司的不同 cDNA 文库。 当结合使用聚合酶反应技术时， 即使极少的表达产物也能克隆。
可用常规方法从这些 cDNA 文库中筛选本发明的基因。 这些方法包括（但不 限于）： （l) DM-DNA 或 DNA - RNA 杂交； （2)标志基因功能的出现或丧失； （3)测 定人转录因子 LCR-F112. 1 的转录本的水平； （4)通过免疫学技术或测定生物学 活性， 来检测基因表达的蛋白产物。 上述方法可单用， 也可多种方法联合应用。
在第（1)种方法中， 杂交所用的探针是与本发明的多核苷酸的任何一部分 同源， 其长度至少 10个核苷酸， 较好是至少 30个核苷酸， 更好是至少 50 个 核苷酸， 最好是至少 100 个核苷酸。 此外， 探针的长度通常在 2000 个核苷酸 之内， 较佳的为 1000 个核苷酸之内。 此处所用的探针通常是在本发明的基因 序列信息的基础上化学合成的 DNA序列。 本发明的基因本身或者片段当然可以 用作探针。 DNA探针的标记可用放射性同位素， 荧光素或酶（如碱性磷酸酶）等。
在第（4)种方法中， 检测人转录因子 LCR-F112. 1 基因表达的蛋白产物可用 免疫学技术如 Wes tern印迹法、 放射免疫沉淀法、 酶联免疫吸附法（ELISA)等。
应 用 PCR 技术 扩增 DNA/RNA 的 方 法 （Sa iki , et a l. Sc ience 1985; 230: 1 350-1 354)被优选用于获得本发明的基因。 特别是很难从文库中得 到全长的 cDNA时，可优选使用 RACE法（RACE - cDNA末端快速扩增法），用于 PCR 的引物可根据本文所公开的本发明的多核苷酸序列信息适当地选择， 并可用常 规方法合成。 可用常规方法如通过凝胶电泳分离和纯化扩增的 DM/RNA片段。
如上所述得到的本发明的基因， 或者各种 DNA 片段等的多核苷酸序列可用 常规方法如双脱氧链终止法（Sanger et a l . PNAS , 1977 , 74 : 5463- 5467)测 定。 这类多核苷酸序列测定也可用商业测序试剂盒等。 为了获得全长的 cDM 序列， 测序需反复进行。 有时需要测定多个克隆的 cDM 序列， 才能拼接成全 长的 cDNA序列。
本发明也涉及包含本发明的多核苷酸的载体， 以及用本发明的载体或直接 用人转录因子 LCR-F112. 1 编码序列经基因工程产生的宿主细胞， 以及经重组 技术产生本发明所述多肽的方法。
本发明中， 编码人转录因子 LCR-F112. 1 的多核苷酸序列可插入到载体中， 以构成含有本发明所述多核苷酸的重组载体。 术语 "载体" 指本领域熟知的细 菌质粒、 噬菌体、 酵母质粒、 植物细胞病毒、 哺乳动物细胞病毒如腺病毒、 逆 转录病毒或其它载体。 在本发明中适用的载体包括但不限于： 在细菌中表达的 基于 T7 启动子的表达载体（Rosenberg, et a l. Gene, 1987, 56: 125) ; 在哺 乳动物细胞中表达的 pMSXND 表达载体（Lee and Nathans, J Bio Chem. 263: 3521, 1988)和在昆虫细胞中表达的来源于杆状病毒的载体。 总之， 只要能 在宿主体内复制和稳定， 任何质粒和载体都可以用于构建重组表达载体。 表达 载体的一个重要特征是通常含有复制起始点、 启动子、 标记基因和翻译调控元 件。
本领域的技术人员熟知的方法能用于构建含编码人转录因子 LCR-F112. 1 的 DM序列和合适的转录 /翻译调控元件的表达载体。这些方法包括体外重组 DM 技术、 DNA合成技术、 体内重组技术等（Sambroook, et al. Molecular Cloning, a Labora tory Manua l , Cold Spring Harbor Laboratory. New York, 1989)。 所述的 DM序列可有效连接到表达载体中的适当启动子上， 以指导 mRM合成。 这些启动子的代表性例子有： 大肠杆菌的 lac 或 trp 启动子； λ噬菌体的 PL 启动子； 真核启动子包括 CMV 立即早期启动子、 HSV 胸苷激酶启动子、 早期和 晚期 SV40启动子、 反转录病毒的 LTRs和其它一些已知的可控制基因在原核细 胞或真核细胞或其病毒中表达的启动子。 表达载体还包括翻译起始用的核糖体 结合位点和转录终止子等。 在载体中插入增强子序列将会使其在高等真核细胞 中的转录得到增强。 增强子是 DNA表达的顺式作用因子， 通常大约有 10到 300 个碱基对， 作用于启动子以增强基因的转录。 可举的例子包括在复制起始点晚 期一侧的 100 到 270个碱基对的 SV40增强子、 在复制起始点晚期一侧的多瘤 增强子以及腺病毒增强子等。
此外， 表达载体优选地包含一个或多个选择性标记基因， 以提供用于选择 转化的宿主细胞的表型性状， 如真核细胞培养用的二氢叶酸还原酶、 新霉素抗 性以及绿色荧光蛋白（GFP)， 或用于大肠杆菌的四环素或氨苄青霉素抗性等。
本领域一般技术人员都清楚如何选择适当的载体 /转录调控元件 （如启动 子、 增强子等） 和选择性标记基因。
本发明中， 编码人转录因子 LCR-F112. 1 的多核苷酸或含有该多核苷酸的 重组载体可转化或转导入宿主细胞， 以构成含有该多核苷酸或重组载体的基因 工程化宿主细胞。 术语 "宿主细胞" 指原核细胞， 如细菌细胞； 或是低等真核 细胞， 如酵母细胞； 或是高等真核细胞， 如哺乳动物细胞。 代表性例子有： 大 肠杆菌， 链霉菌属； 细菌细胞如鼠伤寒沙门氏菌； 真菌细胞如酵母； 植物细胞； 毘虫细胞如果蝇 S2或 Sf9; 动物细胞如 CH0、 COS或 Bowes黑素瘤细胞等。
用本发明所述的 DNA序列或含有所述 DNA序列的重组载体转化宿主细胞可 用本领域技术人员熟知的常规技术进行。 当宿主为原核生物如大肠杆菌时， 能 吸收 DNA 的感受态细胞可在指数生长期后收获， 用 CaCl2法处理， 所用的步骤 在本领域众所周知。 可供选择的是用 MgCl2。 如果需要， 转化也可用电穿孔的 方法进行。 当宿主是真核生物， 可选用如下的 DNA转染方法： 磷酸钙共沉淀法， 或者常规机械方法如显微注射、 电穿孔、 脂质体包装等。
通过常规的重组 DM技术， 利用本发明的多核苷酸序列可用来表达或生产 重组的人转录因子 LCR-F112. 1 (Science, 1984; 224: 1431)。 一般来说有以下 步骤：
(1) 用本发明的编码人 人转录因子 LCR-F112. 1 的多核苷酸 (或变异体）， 或用含有该多核苷酸的重组表达载体转化或转导合适的宿主细胞；
(2) 在合适的培养基中培养宿主细胞；
(3) 从培养基或细胞中分离、 纯化蛋白质。
在步骤（2 ) 中， 根据所用的宿主细胞， 培养中所用的培养基可选自各种 常规培养基。 在适于宿主细胞生长的条件下进行培养。 当宿主细胞生长到适当 的细胞密度后， 用合适的方法（如温度转换或化学诱导）诱导选择的启动子， 将 细胞再培养一段时间。
在步驟 （3 ) 中， 重组多肽可包被于细胞内、 或在细胞膜上表达、 或分泌 到细胞外。 如果需要， 可利用其物理的、 化学的和其它特性通过各种分离方法 分离和纯化重组的蛋白。 这些方法是本领域技术人员所熟知的。 这些方法包括 但并不限于： 常规的复性处理、 蛋白沉淀剂处理（盐析方法）、 离心、 渗透破菌、 超声波处理、 超离心、 分子筛层析（凝胶过滤）、 吸附层析、 离子交换层析、 高 效液相层析 (HPLC)和其它各种液相层析技术及这些方法的结合。 本发明的多肽以及该多肽的拮抗剂、 激动剂和抑制剂可直接用于疾病治 疗， 例如， 可治疗恶性肿瘤、 肾上腺缺乏症、 皮肤病、 各类炎症、 HIV 感染和 免疫性疾病等。
血红蛋白是红血球的主要组成成分， 其在体内负责运送氧气和二氧化碳。 每个血红蛋白分子由两个相同的四个亚基和四个血红素组成， 不含血红素的血 红蛋白成为珠蛋白。 所有的珠蛋白亚基的基因都有十分相似的结构， 在个体发 育的不同阶段， 血红蛋白的亚基组成各不相同。 珠蛋白亚基在体内的转录与表 达受相关转录因子的调控。 转录因子 LCR 即调控着珠蛋白 γ、 ε及 β亚基的转 录与表达， 其先是与含珠蛋白 Ρ亚基基因的染色体结合， 然后再加强珠蛋白 ε、 Υ及 Ρ亚基的转录及表达。 转录因子 LCR- Fl 是一种与已知的转录因子 LCR相似结构与功能的基因， 其蛋白序列中保守的 CNC结构域在珠蛋白 ε、 γ及 β亚基的转录及表达调控过 程中起重要的调节作用， 对于珠蛋白的形成过程中起着重要的调节作用。 该蛋 白的突变或表达异常将导致体内相关珠蛋白的表达异常， 进而影响相关血红蛋 白在体内的作用活性， 即引发各种相关的疾病。
本发明的多肽的表达谱与人转录因子 LCR-F1 的表达谱相一致， 两者具有 相似的生物学功能。 本发明的多肽在体内参与调控珠蛋白 ε、 γ及 Ρ亚基的转 录及表达， 对于珠蛋白的正常形成具有重要意义， 其表达异常将产生红细胞形 成异常， 并产生相关的疾病。
由此可见， 本发明的人转录因子 LCR-F112. 1 的表达异常将产生各种疾病 尤其是红细胞疾病， 这些疾病包括但不限于：
红细胞疾病： 各种贫血， 红细胞增多症， 症状性红细胞增多症， 遗传 性椭圆形细胞增多症。
本发明的多肽以及该多肽的拮抗剂、 激动剂和抑制剂可直接用于疾病治 疗， 例如， 可治疗各种疾病尤其是红细胞疾病等。
本发明也提供了筛选化合物以鉴定提高（激动剂）或阻遏（拮抗剂）人转录因 子 LCR- F112. 1 的药剂的方法。 激动剂提高人转录因子 LCR- F112. 1刺激细胞增 殖等生物功能， 而拮抗剂阻止和治疗与细胞过度增殖有关的紊乱如各种癌症。 例如， 能在药物的存在下， 将哺乳动物细胞或表达人转录因子 LCR- F112. 1 的 膜制剂与标记的人转录因子 LCR- F112. 1 —起培养。 然后测定药物提高或阻遏 此相互作用的能力。
人转录因子 LCR- F112. 1 的拮抗剂包括筛选出的抗体、 化合物、 受体缺失 物和类似物等。人转录因子 LCR-F112. 1的拮抗剂可以与人转录因子 LCR-F112. 1 结合并消除其功能， 或是抑制该多肽的产生， 或是与该多肽的活性位点结合使 该多肽不能发挥生物学功能。
在筛选作为拮抗剂的化合物时， 可以将人转录因子 LCR-F112. 1 加入生物 分析测定中， 通过测定化合物对人转录因子 LCR- F112. 1 和其受体之间相互作 用的影响来确定化合物是否是拮抗剂。 用上述筛选化合物的同样方法， 可以筛 选出起拮抗剂作用的受体缺失物和类似物。 能与人转录因子 LCR-F112. 1 结合 的多肽分子可通过筛选由各种可能组合的氨基酸结合于固相物组成的随机多肽 库而获得。 .筛选时， 一般应对人转录因子 LCR- F112. 1分子进行标记。
本发明提供了用多肽， 及其片段、 衍生物、 类似物或它们的细胞作为抗原 以生产抗体的方法。 这些抗体可以是多克隆抗体或单克隆抗体。 本发明还提供 了针对人转录因子 LCR-F112. 1 抗原决定簇的抗体。 这些抗体包括（但不限于）： 多克隆抗体、 单克隆抗体、 嵌合抗体、 单链抗体、 Fab 片段和 Fab 表达文库产 生的片段。
多克隆抗体的生产可用人转录因子 LCR- F112. 1 直接注射免疫动物 （如家 兔， 小鼠， 大鼠等） 的方法得到， 多种佐剂可用于增强免疫反应， 包括但不限 于弗氏佐剂等。 制备人转录因子 LCR-F112. 1 的单克隆抗体的技术包括但不限 于杂交瘤技术（Kohler and Mi l s tein. Nature, 1975, 256: 495-497) , 三瘤技 术， 人 Β-细胞杂交瘤技术， EBV-杂交瘤技术等。 将人恒定区和非人源的可变区 结合的嵌合抗体可用已有的技术生产（Morr i son et al ， PMS, 1985， 81: 6851)。 而已有的生产单链抗体的技术（U. S. Pat No. 4946778)也可用于生产抗人转录 因子 LCR-F112. 1的单链抗体。
抗人转录因子 LCR-F112. 1 的抗体可用于免疫组织化学技术中， 检测活检 标本中的人转录因子 LCR- F112. 1。
与人转录因子 LCR-F112. 1 结合的单克隆抗体也可用放射性同位素标记， 注入体内可跟踪其位置和分布。 这种放射性标记的抗体可作为一种非创伤性诊 断方法用于肿瘤细胞的定位和判断是否有转移。
抗体还可用于设计针对体内某一特珠部位的免疫毒素。 如人转录因子 LCR- F112. 1 高亲和性的单克隆抗体可与细菌或植物毒素（如白喉毒素， 蓖麻蛋白， 红豆碱等）共价结合。 一种通常的方法是用巯基交联剂如 SPDP， 攻击抗体的氨 基， 通过二硫键的交换， 将毒素结合于抗体上， 这种杂交抗体可用于杀灭人转 录因子 LCR-F112. 1阳性的细胞。
本发明中的抗体可用于治疗或预防与人转录因子 LCR-F112. 1 相关的疾病。 给予适当剂量的抗体可以刺激或阻断人转录因子 LCR-F112. 1的产生或活性。
本发明还涉及定量和定位检测人转录因子 LCR- F112. 1 水平的诊断试验方 法。 这些试验是本领域所熟知的， 且包括 FISH 测定和放射免疫测定。 试验中 所检测的人转录因子 LCR- F112. 1 水平， 可以用作解释人转录因子 LCR-F112. 1 在各种疾病中的重要性和用于诊断人转录因子 LCR-F112. 1起作用的疾病。
本发明的多肽还可用作肽谱分析， 例如， 多肽可用物理的、 化学或酶进行 特异性切割， 并进行一维或二维或三维的凝胶电泳分析，更好的是进行质谱分 析。
编码人转录因子 LCR-F112. 1 的多核苷酸也可用于多种治疗目的。 基因治 疗技术可用于治疗由于人转录因子 LCR-F112. 1 的无表达或异常 /无活性表达所 致的细胞增殖、 发育或代谢异常。 重组的基因治疗载体（如病毒载体）可设计用 于表达变异的人转录因子 LCR- F112. 1， 以抑制内源性的人转录因子 LCR-F112. 1 活性。 例如， 一种变异的人转录因子 LCR-F112. 1 可以是缩短的、 缺失了信号 传导功能域的人转录因子 LCR- F1 12. 1 , 虽可与下游的底物结合， 但缺乏信号传 导活性。 因此， 重组的基因治疗载体可用于治疗人转录因子 LCR- F112. 1 表达 或活性异常所致的疾病。 来源于病毒的表达载体如逆转录病毒、 腺病毒、 腺病 毒相关病毒、 单纯疱疹病毒、 细小病毒等可用于将编码人转录因子 LCR- F112. 1 的多核苷酸转移至细胞内。 构建携带编码人转录因子 LCR-F112. 1 的多核苷酸 的重组病毒载体的方法可见于已有文献（Sarabrook, e t a l. )。 另外， 重组编码 人转录因子 LCR-F112. 1的多核苷酸可包装到脂质体中转移至细胞内。
多核苷酸导入组织或细胞内的方法包括： 将多核苷酸直接注入到体内组织 中； 或在体外通过载体（如病毒、 噬菌体或质粒等）先将多核苷酸导入细胞中， 再将细胞移植到体内等。 ·
抑制人转录因子 LCR-F112. 1 mRNA的寡核苷酸（包括反义 RNA和 DNA)以及 核酶也在本发明的范围之内。 核酶是一种能特异性分解特定 MA的酶样 RNA分 子， 其作用机制是核酶分子与互补的靶 RNA 特异性杂交后进行核酸内切作用。 反义的 RNA和 DNA及核酶可用已有的任何 RNA或 DNA合成技术获得， 如固相磷 酸酰胺化学合成法合成寡核苷酸的技术已广泛应用。 反义 MA 分子可通过编码 该 RNA的 DNA序列在体外或体内转录获得。 这种 DNA序列已整合到载体的 RNA 聚合酶启动子的下游。 为了增加核酸分子的稳定性， 可用多种方法对其进行修 饰， 如增加两侧的序列长度， 核糖核苷之间的连接应用磷酸硫酯键或肽键而非 磷酸二酯键。 '
编码人转录因子 LCR-F112. 1 的多核苷酸可用于与人转录因子 LCR-F112. 1 的相关疾病的诊断。 编码人转录因子 LCR- F112. 1 的多核苷酸可用于检测人转 录因子 LCR- F112. 1 的表达与否或在疾病状态下人转录因子 LCR- F112. 1 的异常 表达。 如编码人转录因子 LCR- F1 12. 1 的 DNA 序列可用于对活检标本进行杂交 以判断人转录因子 LCR-F112. 1 的表达状况。 杂交技术包括 Southern 印迹法、 Nor thern 印迹法、 原位杂交等。 这些技术方法都是公开的成熟技术， 相关的试 剂盒都可从商业途径得到。 本发明的多核苷酸的一部分或全部可作为探针固定 在微阵列（Microarray)或 DNA 芯片（又称为 "基因芯片" ）上， 用于分析组织中 基因的差异表达分析和基因诊断。 用人转录因子 LCR- F112. 1 特异的引物进行 RNA-聚合酶链反应（RT-PCR)体外扩增也可检测人转录因子 LCR-FI U. 1 的转录 产物。
检测人转录因子 LCR-F112. 1 基因的突变也可用于诊断人转录因子 LCR- F112. 1 相关的疾病。 人转录因子 LCR- F112. 1 突变的形式包括与正常野生型人 转录因子 LCR-F112. 1 DNA 序列相比的点突变、 易位、 缺失、 重组和其它任何 异常等。 可用已有的技术如 Southern 印迹法、 DNA序列分析、 PCR和原位杂交 检测突变。另外，突变有可能影响蛋白的表达，因此用 Nor thern印迹法、 Wes tern 印迹法可间接判断基因有无突变。
本发明的序列对染色体鉴定也是有价值的。 该序列会特异性地针对某条人 染色体具体位置并且可以与其杂交。 目前， 需要鉴定染色体上的各基因的具体 位点。 现在， 只有很少的基于实际序列数据（重复多态性）的染色体标记物可用 于标记染色体位置。 根据本发明， 为了将这些序列与疾病相关基因相关联， 其 重要的第一步就是将这些 DNA序列定位于染色体上。
简而言之， 根据 cDNA制备 PCR引物（优选 15-35bp) , 可以将序列定位于 染色体上。 然后， 将这些引物用于 PCR筛选含各条人染色体的体细胞杂合细胞。 只有那些含有相应于引物的人基因的杂合细胞会产生扩增的片段。
体细胞杂合细胞的 PCR定位法， 是将 DNA定位到具体染色体的快捷方法。 使 用本发明的寡核苷酸引物， 通过类似方法， 可利用一组来自特定染色体的片段 或大量基因组克隆而实现亚定位。 可用于染色体定位的其它类似策略包括原位 杂交、 用标记的流式分选的染色体预筛选和杂交预选， 从而构建染色体特异的 cDNA库。
将 cDNA克隆与中期染色体进行荧光原位杂交（FISH) , 可以在一个步骤中精 确地进行染色体定位。此技术的综述参见 Verma等， Human Chromosomes: a Manua l of Bas ic Techniques, Pergamon Pres s, New York (1988)。
一旦序列被定位到准确的染色体位置， 此序列在染色体上的物理位置就可 以与基因图数据相关联。 这些数据可见于 V. Mckus ick, Mendel ian Inher i tance in Man (可通过与 Johns Hopkins Univers i ty Welch Medi ca l Library联机获 得）。 然后可通过连锁分析， 确定基因与业已定位到染色体区域上的疾病之间 的关系。
接着， 需要测定患病和未患病个体间的 cDNA或基因组序列差异。 如果在一 些或所有的患病个体中观察到某突变， 而该突变在任何正常个体中未观察到， 则该突变可能是疾病的病因。 比较患病和未患病个体， 通常涉及首先寻找染色 体中结构的变化， 如从染色体水平可见的或用基于 cDNA序列的 PCR可检测的缺 失或易位。 根据目前的物理作图和基因定位技术的分辨能力， 被精确定位至与 疾病有关的染色体区域的 cDNA, 可以是 50至 500个潜在致病基因间之一种（假定 1兆碱基作图分辨能力和每 20kb对应于一个基因）。
可以将本发明的多肽、 多核苷酸及其模拟物、 激动剂、 拮抗剂和抑制剂与 合适的药物载体组合后使用。 这些载体可以是水、 葡萄糖、 乙醇、 盐类、 缓冲 液、 甘油以及它们的组合。 组合物包含安全有效量的多肽或拮抗剂以及不影响 药物效果的载体和赋形剂。 这些组合物可以作为药物用于疾病治疗。
本发明还提供含有一种或多种容器的药盒或试剂盒， 容器中装有一种或多 种本发明的药用组合物成分。 与这些容器一起， 可以有由制造、 使用或销售药 品或生物制品的政府管理机构所给出的指示性提示， 该提示反映出生产、 使用 或销售的政府管理机构许可其在人体上施用。 此外， 本发明的多肽可以与其它 的治疗化合物结合使用。
药物组合物可以以方便的方式给药， 如通过局部、 静脉内、 腹膜内、 肌内、 皮下、 鼻内或皮内的给药途径。 人转录因子 LCR- F112. 1 以有效地治疗和 /或预 防具体的适应症的量来给药。 施用于患者的人转录因子 LCR-F112. 1 的量和剂 量范围将取决于许多因素， 如给药方式、 待治疗者的健康条件和诊断医生的判 断。 实施例
下面结合具体实施例， 进一步阐述本发明。 应理解， 这些实施例仅用于说 明本发明而不用于限制本发明的范围。 下列实施例中未注明具体条件的实验方 法， 通常按照常规条件如 Sambrook等人， 分子克隆： 实验室手册（New York: Co ld Spr ing Harbor Laboratory Pres s, 1989)中所述的条件， 或按照制造厂 商所建议的条件。
实施例 1 人转录因子 LCR - F112. 1的克隆
用异硫氰酸胍 /酚 /氯仿一步法提取人胎脑总 RNA。 用 Quik mRNA Isolat ion Ki t ( Qiegene 公司产品）从总 RNA中分离 poly (A) mRNA。 2ug poly (A) mRNA经逆转录 形成 cDNA。用 Smart cDM克隆试剂盒（购自 Clontech )将00 片段定向插入到 pBSK (+) 载体 (Clontech公司产品）的多克隆位点上， 转化 DH5 α , 细菌形成 cDM文库。 用 Dye terminate cycle react ion sequencing ki t (Perkin - Elmer公司产品) 和 ABI 377 自动测序仪 (Perkin- Elmer公司）测定所有克隆的 5'和 3'末端的序列。将测定的 cDNA 序列与巳有的公共 DM序列数据库 （Genebank)进行比较， 结果发现其中一个克隆 0080c05的 cDNA序列为新的 DNA。 通过合成一系列引物对该克隆所含的插入 cDNA片 段进行双向测定。结果表明， 0080c05克隆所含的全长 cDNA为 1474bp (如 Seq IDN0: l 所示） , 从第 968bp至 1300bp有一个 332bp的开放阅读框架 （ 0RF ) ， 编码一个新 的蛋白质 (如 Seq ID NO: 2所示） 。 我们将此克隆命名为 pBS-0080c05 , 编码的蛋 白质命名为人转录因子 LCR - F112.1。 实施例 2 用 RT-PCR方法克隆编码人转录因子 LCR- F112.1的基因
用胎脑细胞总 ΜΑ为模板，以 oligo- dT为引物进行逆转录反应合成 cDNA，用 Qiagene的试剂盒纯化后，用下列引物进行 PCR扩增：
Primerl: 5，_ GGGGTTGGAAACCAGTCCCCCACA -3' (SEQ ID NO: 3)
Primer2: 5'- TTCATAGCAGCTTTATTCATAACA -3' (SEQ ID NO: 4)
Primerl为位于 SEQ ID NO: 1的 5，端的第 lbp开始的正向序列；
Primer2为 SEQ ID NO: 1的中的 3，端反向序列。
扩增反应的条件： 在 50μ1的反应体积中含有 50mmol/LKCl, 10mmol/L Tr is-HCl pH8.5，1.5mmol/L MgCl2, 200 mol/L dNTP, lOpmol引物， 1ϋ的 Taq DNA聚合酶 (Clontech公司产品）。 在 PE9600型 DNA热循环仪（Perkin-Elmer公司）上按下列条件 反应 25个周期: 94°C 30sec; 55。C 30sec; 72°C 2min。 在 RT-PCR时同时设 β -act in 为阳性对照和模板空白为阴性对照。 扩增产物用 QIAGEN公司的试剂盒纯化， 用 TA 克隆试剂盒连接到 pCR载体上（Invitrogen公司产品） 。 DNA序列分析结果表明 PCR 产物的 DM序列与 SEQ ID NO: 1所示的 l-1474bp完全相同。 实施例 3 Northern 印迹法分析人转录因子 LCR-F112.1基因的表达 用一步法提取总 RNA[Anal. Biochem 1987, 162, 156-159] 0 该法包括酸性硫 氰酸胍苯酚-氯仿抽提。 即用 4M异硫氰酸胍 -25mM柠檬酸钠， 0.2M乙酸钠 （ pH4.0 ) 对组织进行匀浆， 加入 1倍体积的苯酚和 1/5体积的氯仿-异戊醇 （49: 1 ) , 混合 后离心。 吸出水相层， 加入异丙醇 （0.8体积） 并将混合物离心得到 RM沉淀。 将 得到的 RNA沉淀用 70%乙醇洗涤， 干燥并溶于水中。 用 2(^g RNA, 在含 20mM 3- ( N- 吗啉代 ) 丙磺酸 ( H7.0 ) - 5mM乙酸钠 -ImM EDTA-2.2M甲醛的 1.2%琼脂糖凝胶上进 行电泳。 然后转移至硝酸纤维素膜上。 用 a-32P dATP通过随机引物法制备 32Ρ-标记 的 DM探针。 所用的 DNA探针为图 1所示的 PCR扩增的人转录因子 LCR-F112.1编码区 序列（968bp至 1300bp)。 将 32P-标记的探针 (约 2 χ 106cpm/ml ) 与转移了 RM的硝 酸纤维素膜在一溶液中于 42°C杂交过夜， 该溶液包含 50%甲酰胺 -25mM KH2P04 ( Η7.4 ) -5 χ SSC-5 χ Denhardt's溶液和 20(^g/ml鲑精 DNA。 杂交之后， 将滤膜在 1 X SSC- 0.1%SDS中于 55°C洗 30min。 然后， 用 Phosphor Imager进行分析和定量。 实施例 4 重组人转录因子 LCR-F112.1的体外表达、 分离和纯化
根据 SEQ ID NO: 1和图 1所示的编码区序列， 设计出一对特异性扩增引物， 序 列如下：
Primer 3: 5 '-CCCCATATGATGCATCACCACACCCAGCTAATT-3 ' ( Seq ID No: 5 ) Primer4: 5'-CATGGATCCTTACATTAAGTGAAAGAAGCTGGA-3' ( Seq ID No: 6 ) 此两段引物的 5'端分别含有 Mel和 BamHI酶切位点， 其后分别为目的基因 5'端 和 3'端的编码序列， Ndel和 BamHI酶切位点相应于表达载体质粒 pET - 28b(+) (Novagen公司产品， Cat. No.69865.3)上的选择性内切酶位点。 以含有全长 目的基因的 pBS-0080c05质粒为模板， 进行 PCR反应。 PCR反应条件为： 总体积 50μ1 中含 pBS - 0080c05质粒 10pg、 引物 Primer- 3和 Primer- 4分另 !j为 lOpmol、 Advantage polymerase Mix (Clontech公司产品） 1μ1。 循环参数: 94°C 20s, 60°C 30s, 68°C 2 min,共 25个循环。 用 Ndel和 BamHI分别对扩增产物和质粒 pET-28 (+)进行双酶切，分 别回收大片段，并用 T4连接酶连接。 连接产物转化用氯化钙法大肠杆细菌 DH5a，在 含卡那霉素 （终浓度 30 g/ml ) 的 LB平板培养过夜后， 用菌落 PCR方法筛选阳性克 隆， 并进行测序。 挑选序列正确的阳性克隆（PET- 0080c05 )用氯化钙法将重组质 粒转化大肠杆菌 BL21 (DE3)plySs(Novagen公司产品）。 在含卡那霉素 （终浓度 30μ§/πι1 ) 的 LB液体培养基中， 宿主菌 BL21 ( PET-0080c05 ) 在 37。C培养至对数生 长期， 加入 IPTG至终浓度 lmmol/L, 继续培养 5小时。 离心收集菌体， 经超声波破 菌，离心收集上清，用能与 6个组氨酸（6His-Tag)结合的亲和层析柱 His. Bind Quick Cartridge ( Novagen公司产品） 进行层析， 得到了纯化的目的蛋白人转录因子 LCR-F112. K 经 SDS-PAGE电泳， 在 12kDa处得到一单一的条带 （图 2 ) 。 将该条带 转移至 PVDF膜上用 Edams水解法进行 N-端氨基酸序列分析， 结果 N-端 15个氨基酸与 SEQ ID NO: 2所示的 N-端 15个氨基酸残基完全相同。 实施例 5 抗人转录因子 LCR-F112.1抗体的产生
用多肽合成仪（PE公司产品）合成下述人转录因子 LCR-F112.1特异性的多肽： NH2-Met-His-His-His-Thr-Gln-Leu-Ile-Ser-Val-Phe-Phe-Val-Glu-Thr-C00H (SEQ ID NO: 7)。 将该多肽分别与血蓝蛋白和牛血清白蛋白耦合形成复合物， 方法 参见： Avrameas, et al. Immunochemis try, 1969; 6: 43。 用 ½g上述血蓝蛋白多肤 复合物加上完全弗氏佐剂免疫家兔， 15天后再用血蓝蛋白多肽复合物加不完全弗 氏佐剂加强免疫一次。 釆用经 15 g/ml牛血清白蛋白多肽复合物包被的滴定板做 ELISA测定兔血清中抗体的滴度。 用蛋白 A-Sepharose从抗体阳性的家兔血清中分 离总 IgG。 将多肽结合于溴化氰活化的 Sepharose4B柱上， 用亲和层析法从总 IgG中 分离抗多肽抗体。免疫沉淀法证明纯化的抗体可特异性地与人转录因子 LCR-F112. 1 结合。 实施例 6 本发明的多核苷酸片段用作杂交探针的应用
从本发明的多核苷酸中挑选出合适的寡核苷酸片段用作杂交探针有多方面的 用途， 如用该探针可与不同来源的正常组织或病理组织的基因组或 cDM文库杂交 以鉴定其是否含有本发明的多核苷酸序列和检出同源的多核苷酸序列，进一步还可 用该探针检测本发明的多核苷酸序列或其同源的多核苷酸序列在正常组织或病理 组织细胞中的表达是否异常。
本实施例的目的是从本发明的多核苷酸 SEQ ID NO: 1 中挑选出合适的寡核苷 酸片段用作杂交探针， 并用滤膜杂交方法鉴定一些组织中是否含有本发明的多核 苷酸序列或其同源的多核苷酸序列。 滤膜杂交方法包括斑点印迹法、 Southern 印 迹法、 Northern 印迹法和复印方法等， 它们都是将待测的多核苷酸样品固定在滤 膜上后使用基本相同的步骤杂交。 这些相同的步骤是： 固定了样品的滤膜首先用 不含探针的杂交缓冲液进行预杂交， 以使滤膜上样品的非特异性的结合部位被载 体和合成的多聚物所饱和。 然后预杂交液被含有标记探针的杂交缓冲液替换， 并 保温使探针与靶核酸杂交。 杂交步骤之后， 未杂交上的探针被一系列洗膜步骤除 掉。 本实施例利用较高强度的洗膜条件（如较低盐浓度和较高的温度）， 以使杂交 背景降低且只保留特异性强的信号。 本实施例选用的探针包括两类： 第一类探针 是完全与本发明的多核苷酸 SEQ ID NO: 1相同或互补的寡核苷酸片段； 第二类探 针是部分与本发明的多核苷酸 SEQ ID NO: 1相同或互补的寡核苷酸片段。 本实施 例选用斑点印迹法将样品固定在滤膜上， 在较高强度的的洗膜条件下， 第一类探 针与样品的杂交特异性最强而得以保留。
一、 探针的选用
从本发明的多核苷酸 SEQ ID NO: 1中选择寡核苷酸片段用作杂交探针， 应遵 循以下原则和需要考虑的几个方面：
1， 探针大小优选范围为 18-50个核苷酸； 2, GC含量为 30%-70%, 超过则非特异性杂交增加；
3, 探针内部应无互补区域；
4, 符合以上条件的可作为初选探针， 然后进一步作计算机序列分析， 包括将 该初选探针分别与其来源序列区域 （即 SEQ ID NO: 1)和其它巳知的基因组序列 及其互补区进行同源性比较， 若与非靶分子区域的同源性大于 85%或者有超过 15 个连续碱基完全相同， 则该初选探针一般就不应该使用；
5， 初选探针是否最终选定为有实际应用价值的探针还应进一步由实验确定。 完成以上各方面的分析后挑选并合成以下二个探针：
探针 1 (probel), 属于第一类探针， 与 SEQ ID NO: 1 的基因片段完全同源 或互补 (41Nt):
5'-TGCATCACCACACCCAGCTAATTTCTGTATTTTTTGTAGAG-3' ( SEQ ID NO: 8) 探针 2 (probe2 ), 属于第二类探针， 相当于 SEQ ID NO: 1 的基因片段或其 互补片段的替换突变序列 （41Nt):
5'-TGCATCACCACACCCAGCTACTTTCTGTATTTTTTGTAGAG-3' ( SEQ ID NO: 9 ) 与以下具体实验步骤有关的其它未列出的常用试剂及其配制方法请参考文 献： 丽 PROBES G.H. Keller; M.M.Manak; Stockton Press, 1989 (USA)以及更常 用的分子克隆实验手册书籍如 《分子克隆实验指南》（ 1998年第二版） [美]萨姆布 鲁克等著， 科学出版社。
样品制备：
1 , 从新鲜或冰冻组织中提取 DNA
步骤： 1)将新鲜或新鲜解冻的正常肝组织放入浸在冰上并盛有磷酸盐缓冲液 (PBS) 的平 J 中。 用剪刀或手术刀将组织切成小块。 搡作中应保持组织湿润。 2) 以 lOOOg离心切碎组织 10分钟。 3)用冷匀浆缓冲液 ( 0.25mol/L蔗糖； 25mmol/L Tris-HCl,pH7.5; 25mraol/L NaCl; 25mmol/L MgCl2 ) 悬浮沉淀（大约 lOml/g )。 4) 在 4°C 用电动匀浆器以全速匀浆组织悬液， 直至组织被完全破碎。 5) lOOOg 离心 10分钟。 6)用重悬细胞沉淀（每 0. lg最初组织样品加 1- 5ml)， 再以 1000g离心 10分钟。 7)用裂解缓冲液重悬沉淀（每 O.lg最初组织样品加 lml), 然后接以下 的苯酚抽提法。
2， DNA的苯酚抽提法
步骤： 1)用 l-10ml冷 PBS洗细胞， lOOOg离心 10分钟。 2)用冷细胞裂解 液重悬浮沉淀的细胞 （lxlO8细胞 /ml) 最少应用 lOOul 裂解缓冲液。 3)加 SDS 至终浓度为 1%, 如果在重悬细胞之前将 SDS直接加入到细胞沉淀中， 细胞可能会 形成大的团块而难以破碎， 并降低总产率。 这一点在抽提 >107细胞时特别严重。 4) 加蛋白酶 K至终浓度 200ug/ml。 5) 50°C保温反应 1小时或在 37°C轻轻振摇过夜。 6)用等体积苯酚： 氯仿： 异戊醇 （ 25: 24: 1 )抽提， 在小离心机管中离心 10分 钟。 两相应清楚分离， 否则重新进行离心。 7 ) 将水相转移至新管。 8 )用等体积 氯仿： 异戊醇 （24: 1)抽提， 离心 10分钟。 9)将含 DM的水相转移至新管。 然 后进行 DNA的纯化和乙醇沉淀。
3, DNA的纯化和乙醇沉淀
步骤： 1 )将 1/10体积 2mol/L醋酸钠和 1倍体积冷 100%乙醇加到 DNA溶液 中， 混匀。 在- 20°C放置 1小时或过夜。 2) 离心 10分钟。 3)小心吸出或倒出乙 醇。 4)用 70%冷乙醇 500ul洗涤沉淀， 离心 5分钟。 5)小心吸出或倒出乙醇。 用 500ul 冷乙醇洗涤沉淀， 离心 5 分钟。 6)小心吸出或倒出乙醇， 然后在吸水纸上 倒置使残余乙醇流尽。 空气干燥 10 - 15 分钟， 以使表面乙醇挥发。 注意不要使沉 淀完全干燥， 否则较难重新溶解。 7) 以小体积 TE或水重悬 DNA沉淀。 低速涡旋 振荡或用滴管吹吸， 同时逐渐增加 TE，.混合至 DNA充分溶解， 每 1- 5 χ 10δ细胞所 提取的大约加 lul。
以下第 8-13步骤仅用于必须除去污染时， 否则可直接进行第 14步骤。
8 )将 RM酶 A加到 DM溶液中， 终浓度为 lOOug/ml, 37°C保温 30分钟。 9) 加入 SDS和蛋白酶 ， 终浓度分别为 0.5%和 100ug/ml。 37°C保温 30分钟。 10) 用等体积的苯酚： 氯仿： 异戊醇 （ 25: 24： 1 )抽提反应液， 离心 10 分钟。 11 ) 小心移出水相， 用等体积的氯仿： 异戊醇（24: 1 ) 重新抽提， 离心 10分钟。 12) 小心移出水相， 加 1八0体积 2mol/L醋酸钠和 2.5体积冷乙醇， 混匀置 -20°C 1小 时。 13)用 70%乙醇及 100%乙醇洗涤沉淀， 空气干燥， 重悬核酸， 过程同笫 3-6 步骤。 14)测定 A26fl和 A28Q以检测 DNA的纯度及产率。 15)分装后存放于 - 20°C。
样膜的制备：
1 )取 4 x 2 张适当大小的硝酸纤维素膜（NC 膜）， 用铅笔在其上轻轻标出 点样位置及样号， 每一探针需两张 NC膜， 以便在后面的实验步骤中分别用高强度 条件和强度条件洗膜 。
2) 吸取及对照各 15微升， 点于样膜上， 在室温中晾干。
3 ) 置于浸润有 0. lmol/L NaOH, 1.5mol/L NaCl的滤纸上 5分钟 (两次）， 晾干置于浸润有 0.5mol/L Tris-HCl ( pH7.0 ), 3mol/L NaCl的滤纸上 5分钟 （两 次）， 晾干。
4)夹于干净滤纸中， 以铝箔包好， 60-80°C真空干燥 2小时。 探针的标记
1) 3μ1 Probe ( 0.擺/ΙΟμΙ )， 加入 2μ1 Kinase缓冲液， 8-10 uCi γ-32Ρ- dATP+2U Kinase, 以补加至终体积 20μ1。
2) 37 °C 保温 2小时。
3)加 1/5体积的溴酚蓝指示剂 (BPB)。
4 ) 过 Sephadex G- 50柱。
5 ) 至有 32P-Probe洗出前开始收集第一峰（可用 Monitor监测；)。
6) 5滴 /管， 收集 10-15管。
7)用液体闪烁仪监测同位素量。
8)合并第一峰的收集液后即为所需制备的 32P-Probe (第二峰为游离 γ- 32P - dATP )。
预杂交
将样膜置于塑料袋中，加入 3- lOmg预杂交液（ lOxDenhardt-s; 6xSSC， 0. lmg/ml CT DNA (小牛胸腺 DM))。 封好袋口后， 68°C水浴摇 2小时。
杂交
将塑料袋剪去一角， 加入制备好的探针， 封好袋口后， 42 水浴摇过夜。 洗膜：
高强度洗膜：
1)取出已杂交好的样膜。
2 ) 2xSSC, 0.1%SDS中， 40。C洗 15分钟 (2次）。
3) 0. IxSSC, 0.1°/。SDS中， 40°Ci洗 15分钟 （ 2次）。
4 ) 0. IxSSC, 0.1%SDS中， 55。C洗 30分钟 （ 2次）， 室温晾干。 低强度洗膜：
1)取出已杂交好的样膜。
2 ) 2xSSC, 0.1 SDS中， 37°C洗 15分钟 （ 2次）。
3 ) 0. IxSSC, 0.1%SDS中， 37°C洗 15分钟 （ 2次）。
4 ) 0. IxSSC, 0.1%SDS中， 40°C洗 15分钟 ( 2次）, 室温晾干。
X -光自显影：
-70°C, X-光自显影 （压片时间根据杂交斑放射性强弱而定)。 实验结果：
采用低强度洗膜条件所进行的杂交实验， 以上两个探针杂交斑放射性强弱没 有明显区别； 而采用高强度洗膜条件所进行的杂交实验， 探针 1 的杂交斑放射性 强度明显强于另一个探针杂交斑的放射性强度。 因而可用探针 1 定性和定量地分 析本发明的多核苷酸在不同组织中的存在和差异表达。 实施例 7 DNA Microarray
基因芯片或基因微矩阵 （DNA Microarray )是目前许多国家实验室和大制药 公司都在着手研制和开发的新技术， 它是指将大量的靶基因片段有序地、 高密度 地排列在玻璃、 硅等载体上， 然后用荧光检测和计算机软件进行数据的比较和分 析， 以达到快速、 高效、 高通量地分析生物信息的目的。 本发明的多核苷酸可作 为靶 DNA 用于基因芯片技术用于高通量研究新基因功能； 寻找和筛选组织特异性 新基因特别是肿瘤等疾病相关新基因； 疾病的诊断， 如遗传性疾病。 其具体方法 步骤在文献中已有多种报道， 如可参阅文献 DeRis i, L L. , Lyer, V. &Brown, P. 0. (1997) Science 278, 680-686.及文献 Hel le, R. A. , Schema, M. , Chai, A. , Shalom, D.， (1997) PNAS 94: 2150-2155.
(一） 点样
各种不同的全长 cDNA共计 4000条多核苷酸序列作为靶 DM,其中包括本发明 的多核苷酸。 将它们分别通过 PCR 进行扩增， 纯化所得扩增产物后将其浓度调到 500ng/ul左右, 用 Cartes ian 7500点样仪（购自美国 Cartes ian公司）点于玻璃介 质上， 点与点之间的距离为 280μπι。 将点样后的玻片进行水合、 干燥， 置于紫外 交联仪中交联， 洗脱后干燥使 DNA 固定在玻璃片上制备成芯片。 其具体方法步骤 在文献中已有多种报道。 本实施例的点样后处理步骤是：
1. 潮湿环境中水合 4小时；
2. 0. 2°/。SDS洗涤 1分钟；
3. ddH20洗涤两次， 每次 1分钟；
4. NaBH4封闭 5分钟；
5. 95°C水中 2分钟；
6. 0. 2%SDS洗涤 1分钟;
7. ddH20冲洗两次；
8. 凉干， 25°C储存于暗处备用。 (二）探针标记
用一步法分别从人体混合组织与机体特定组织 （或经过刺激的细胞株） 中抽 提总 mRNA, 并用 Ol igotex mRNA Midi Ki t (购自 QiaGen公司）纯化 mRNA,通过反转 录分另1 J将荧光试剂 Cy3dUTP (5-Amino-propargyl-2--deoxyuridine 5>-triphate coupled to Cy3 f luorescent dye, 购自 Amersham Phamacia Biotech公司)标记 人体混合组织的 mRNA, 用荧光试剂 Cy5d(JTP (5- Amino- propargyl- 2'- deoxyuridine 5'-triphate coupled to Cy5 f luorescent dye, 购自 Amersham Phamacia Biotech 公司）标记机体特定组织 （或经过刺激的细胞株） mRNA, 经纯化后制备出探针。 具 体步骤参照及方法见：
Schena, M. , Shalon, D. , Heller, R. (1996) Proc. Natl. Acad. Sci. USA. Vol. 93: 10614-10619. Schena, M. , Sha lon, Dar i . , Dav i s , R. W. (1995) Sc i ence. 270. (20) : 467-480.
(三） 杂交
分别将来自以上两种组织的探针与芯片一起在 UniHyb™ Hybridizat ion Solut ion (购自 TeleChem公司）杂交液中进行杂交 16 小时， 室温用洗涤液 （l x SSC, 0. 2¾SDS ) 洗涤后用 ScanArray 3000扫描仪 （购自美国 General Scanning公 司）进行扫描， 扫描的图象用 Imagene软件（美国 Biodi scovery公司）进行数据 分析处理， 算出每个点的 Cy3/Cy5比值。
以上机体特定组织 （或经过刺激的细胞株）分别为胎脑、 膀胱粘膜、 PMA+的 Ecv304细胞株、 LPS+的 Ecv304细胞株胸腺、 正常成纤维细胞 1024NC、 Fibroblas t , 生长因子刺激， 1024NT、 疤痕成 fc生长因子刺激， 1013HT、 疤痕成 fc未用生长因 子刺激， 1 G13HC、 膀胱癌建株细胞 EJ、 膀胱癌旁、 膀胱癌、 肝癌、 肝癌细胞株、 胎皮、 脾脏、 前列腺癌、 空肠腺癌、 贲门癌。 根据这 18个 Cy3/Cy5比值绘出折方图 (图 1 ) 。 由图可见本发明所述的人转录因子 LCR- F112. 1和人转录因子 LCR-F1表达

Claims

权利要隶
1、一种分离的多肽——人转录因子 LCR- F1 12. 1，其特征在于它包含有： SEQ ID N0: 2所示的氨基酸序列的多肽、 或其多肽的活性片段、 类似物或衍生物。
2、 如权利要求 1 所述的多肽， 其特征在于所述多肽、 类似物或衍生物的 氨基酸序列具有与 SEQ ID NO: 2所示的氨基酸序列至少 95%的相同性。
3、 如权利要求 2所述的多肽， 其特征在于它包含具有 SEQ ID NO: 2 所示 的氨基酸序列的多肽。
4、 一种分离的多核苷酸， 其特征在于所述多核苷酸包含选自下组中的一 种：
(a)编码具有 SEQ ID NO: 2 所示氨基酸序列的多肽或其片段、 类似物、 衍 生物的多核苷酸；
(b)与多核苷酸 （a ) 互补的多核苷酸； 或
(c)与 ( a )或 （b ) 有至少 70%相同性的多核苷酸。
5、 如权利要求 4 所述的多核苷酸， 其特征在于所述多核苷酸包含编码具 有 SEQ ID NO: 2所示氨基酸序列的多核苷酸。
6、 如杈利要求 4 所述的多核苷酸， 其特征在于所述多核苷酸的序列包含 有 SEQ ID NO: 1中 968- 1 300位的序列或 SEQ ID NO: 1中 1-1474位的序列。
7、 一种含有外源多核苷酸的重组载体， 其特征在于它是由杈利要求 4 - 6 - 中的任一杈利要求所述多核苷酸与质粒、 病毒或运载体表达载体构建而成的重 组载体。
8、 一种含有外源多核苷酸的遗传工程化宿主细胞， 其特征在于它是选自 于下列一种宿主细胞：
(a) 用权利要求 7所述的重组载体转化或转导的宿主细胞； 或
(b) 用权利要求 4- 6 中的任一杈利要求所述多核苷酸转化或转导的宿主细 胞。
9、 一种具有人转录因子 LCR-F112. 1活性的多肽的制备方法， 其特征在于 所述方法包括：
(a) 在表达人转录因子 LCR-F112. 1 条件下， 培养权利要求 8所述的工程 化宿主细胞；
(b) 从培养物中分离出具有人转录因子 LCR- F112. 1活性的多肽。
1 0、 一种能与多肽结合的抗体，其特征在于所述抗体是能与人转录因子 LCR-F112. 1特异性结合的抗体。
11、 一类模拟或调节多肽活性或表达的化合物， 其特征在于它们是模拟、 促进、 拮抗或抑制人转录因子 LCR-F112. 1的活性的化合物。
12、 如杈利要求 11 所述的化合物， 其特征在于它是 SEQ ID N0: 1 所示的 多核苷酸序列或其片段的反义序列。
13、 一种权利要求 11 所述化合物的应用， 其特征在于所述化合物用于调 节人转录因子 LCR-F112. 1在体内、 体外活性的方法。
14、 一种检测与权利要求 1-3中的任一权利要求所述多肽相关的疾病或疾 病易感性的方法， 其特征在于其包括检测所述多肽的表达量， 或者检测所述多 肽的活性， 或者检测多核苷酸中引起所述多肽表达量或活性异常的核苷酸变 异。
15、 如权利要求 1-3中的任一权利要求所述多肽的应用， 其特征在于它应 用于筛选人转录因子 LCR-F112. 1 的模拟物、 激动剂、 拮抗剂或抑制剂； 或者 用于肽指紋图谱鉴定。
16、 如杈利要求 4-6 中的任一杈利要求所述的核酸分子的应用， 其特征在 于它作为引物用于核酸扩增反应， 或者作为探针用于杂交反应， 或者用于制造 基因芯片或微阵列。
17、 如权利要求 1-6及 11 中的任一杈利要求所述的多肽、 多核苷酸或化 合物的应用， 其特征在于用所述多肽、 多核苷酸或其模拟物、 激动剂、 拮抗剂 或抑制剂以安全有效剂量与药学上可接受的载体组成作为诊断或治疗与人转录 因 J; LCR- F112. 1异常相关的疾病的药物组合物。
18、 权利要求 1-6及 11 中的任一权利要求所述的多肽、 多核苷酸或化合 物的应用， 其特征在于用所述多肽、 多核苷酸或化合物制备用于治疗如恶性肿 瘤， 血液病， HIV感染和免疫性疾病和各类炎症的药物。
PCT/CN2001/001094 2000-06-30 2001-06-29 Nouveau polypeptide, facteur de transcription humain lcr-f112.1, et polynucleotide codant ce polypeptide WO2002026971A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002210328A AU2002210328A1 (en) 2000-06-30 2001-06-29 A novel polypeptide- human transcription factor lcr-f112.1 and the polynucleotide encoding said polypeptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN00116953.X 2000-06-30
CN 00116953 CN1331226A (zh) 2000-06-30 2000-06-30 一种新的多肽——人转录因子lcr－f112.1和编码这种多肽的多核苷酸

Publications (1)

Publication Number Publication Date
WO2002026971A1 true WO2002026971A1 (fr) 2002-04-04

Family

ID=4586352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2001/001094 WO2002026971A1 (fr) 2000-06-30 2001-06-29 Nouveau polypeptide, facteur de transcription humain lcr-f112.1, et polynucleotide codant ce polypeptide

Country Status (3)

Country Link
CN (1) CN1331226A (zh)
AU (1) AU2002210328A1 (zh)
WO (1) WO2002026971A1 (zh)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHENG JUN ET AL.: "Transcription factor nur77 expression in apoptotic cells induced by anti-CD95 monoclonal antibody", IMMUNOLOGICAL JOURNAL, vol. 15, no. 3, July 1999 (1999-07-01), pages 177 - 179 *
DATABASE PROTEIN [online] 2 August 1994 (1994-08-02), CATERINA J.J. ET AL., retrieved from GI:520471 accession no. NCBI Database accession no. (AAA20466.1) *
DATABASE PROTEIN [online] 5 November 1999 (1999-11-05), CATERINA J.J. ET AL., retrieved from GI:627656 accession no. NCBI Database accession no. (A55004) *

Also Published As

Publication number Publication date
AU2002210328A1 (en) 2002-04-08
CN1331226A (zh) 2002-01-16

Similar Documents

Publication Publication Date Title
WO2002026971A1 (fr) Nouveau polypeptide, facteur de transcription humain lcr-f112.1, et polynucleotide codant ce polypeptide
WO2001092518A1 (fr) Nouveau polypeptide, proteine humaine 9.5 associee a la ccr4, et polynucleotide codant ce polypeptide
WO2002012297A1 (fr) Nouveau polypeptide, proteine humaine 9 de liaison a la tropomoduline, et polynucleotide codant ce polypeptide
WO2001090133A1 (fr) Nouveau polypeptide, uracil desoxyribonucleotide glycosylase humaine 22, et polynucleotide codant ce polypeptide
WO2001094579A1 (fr) Nouveau polypeptide, proteine humaine 8.8 d'activation de gm2, et polynucleotide codant ce polypeptide
WO2001048006A1 (fr) Nouveau polypeptide, proteine de liaison de la cobalamine 10, et polynucleotide codant pour ce polypeptide
WO2001092541A1 (fr) Nouveau polypeptide, catalase 12, et polynucleotide codant ce polypeptide
WO2001075048A2 (fr) Nouveau polypeptide, proteine ribosomale humaine s11 23, et polynucleotide codant pour ce polypeptide
WO2002012315A1 (fr) Nouveau polypeptide, proteine mid1 10.56 du gene de type « ring finger », et polynucleotide codant ce polypeptide
WO2002026791A1 (fr) Nouveau polypeptide, serine kinase 212.98 specifique d'une proteine sr, et polynucleotide codant ce polypeptide
WO2002012314A1 (en) A novel polypeptide - human dihydropyrimidinase-related protein-1(drp-1) 9.68 and a polynucleotide encoding the same
WO2002006471A1 (fr) Nouveau polypeptide, nucleophosmine 9.68, et polynucleotide codant ce polypeptide
WO2001092315A1 (en) A novel polypeptide, a human splicing protein 10.56 and the polynucleotide encoding the polypeptide
WO2001085752A1 (fr) Polynucleotide codant un peptide de myosine
WO2001094537A2 (en) Novel polypeptide--human nadh ubiquinone oxidoreductase 21.89 and polynucleotide encoding it
WO2002020575A1 (fr) Nouveau polypeptide, proteine humaine 10 associee aux maladies auto-immunes, et polynucleotide codant ce polypeptide
WO2002020583A1 (fr) Nouveau polypeptide, facteur humain de transcription lcr-f19.02, et polynucleotide codant ce polypeptide
WO2002020743A1 (fr) Nouveau polypeptide, i-kappa b kinase humaine 15, et polynucleotide codant ce polypeptide
WO2001094534A2 (fr) Nouveau polypeptide, facteur humain de transcription 9.57, et polynucleotide codant ce polypeptide
WO2002006473A1 (fr) Nouveau polypeptide, proteine humaine 10.01 associee au recepteur d'oestrogene, et polynucleotide codant ce polypeptide
WO2001070792A1 (fr) Nouveau polypeptide, tyrosinase humaine 12, et polynucleotide codant pour ce polypeptide
WO2001073041A1 (fr) Nouveau polypeptide, adn ligase humaine 15, et polynucleotide codant pour ce polypeptide
WO2001090131A1 (fr) Nouveau polypeptide, proteine humaine 10.56 du gene cancerigene tre, et polynucleotide codant ce polypeptide
WO2001083676A2 (en) A novel polypeptide human strip-riched phosphatase 10 and the polynucleotide encoding said polypeptide
WO2001074894A1 (fr) Nouveau polypeptide, proteine humaine de regulation 12 de la proteine phosphorylase, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP